NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON

DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS

5   *Related Applications*

The present application is a Continuation-In-Part of United States Provisional Patent Applications Serial Nos. 60/079,764, filed 27-March-1998, and 60/093,208, filed 17-July-1998; these applications are incorporated herein by reference, and priority is claimed from these applications.

Background of Invention

1. Field of the Invention

15   The present invention concerns the medical area of treatment of viral infections and more particularly includes novel inhibitors of HIV integrase and combination drug therapies including integrase inhibitors.

2. Description of the Prior Art

Infection of an individual with the human immunodeficiency virus (HIV) is 20   understood to be the first step toward the development of acquired immunodeficiency syndrome (AIDS) disease. In nearly all cases where individuals receive no treatment for HIV infection, the proliferation of the virus gives rise to AIDS. As of early 1999, an estimated 33.4 million people are infected with HIV worldwide. Furthermore, the number of people worldwide that became infected with HIV during 1998 is estimated 25   to be 5.8 million. It has also been observed that the annual rate of new infection with

HIV in the entire human population is not declining. Despite this fact, the rate of death due to AIDS has begun to drop in some nations, including the United States, primarily through the recent use of combination drug therapies against HIV infection.

5   The means by which such therapies counter HIV infection is best understood with reference to the biological mechanisms of the HIV life cycle. HIV is a member of a class of infectious agents known as retroviruses. The infectious form of HIV, a virion, is a particle that consists of a viral genome composed of RNA that is surrounded by proteins encoded by the genome. Infection occurs when an HIV virion enters a susceptible host cell, such as a T lymphocyte within the bloodstream. At this

10   point, one of the viral proteins that comprised the virion, reverse transcriptase (RT), synthesizes a double-stranded DNA copy of the HIV RNA genome. The resulting HIV DNA enters the cell nucleus as part of a stable complex with other virion proteins. This complex contains all the necessary molecular apparatus for integration of the HIV DNA into the host cell's nuclear DNA. Integration, wherein the HIV DNA

15   is covalently inserted into the host cell's genomic DNA, is absolutely required for productive HIV infection. It is only after integration that the HIV DNA can serve as the template for the production of HIV proteins and RNA that will comprise progeny virions. Among these viral proteins is the HIV protease, the activity of which is necessary for proper formation of new virions. This process, from viral entry to new

20   virion production, is termed viral replication. Upon release from an infected host cell, the newly produced virions are capable of infecting more, previously uninfected host cells. It is through successive rounds of HIV replication and productive host cell infection that HIV disease spreads throughout numerous host cells and ultimately progresses to AIDS disease.

25   Currently, the best clinical results in HIV treatment come from the use of combination drug therapies. These therapies consist of the simultaneous administration of multiple drugs, which potently and selectively target different elements of the HIV life cycle to disrupt or forestall productive HIV infection and progression to AIDS. The potency of a drug refers to its capacity to act efficaciously

at as low a dose as possible, preferably at levels well below those that result in significant amounts of cell death or other signs of cellular toxicity. Selectivity describes the propensity of the drug to act upon a specific target such as unique kind of viral protein. Both of these attributes are of practical importance in the design of

5   therapeutic regimens as they determine the dose, and thus the frequency, cost, and degree of side effects that may occur with use. A further benefit that stems from the use of combinations of drugs derives from a phenomenon known as synergism. With regards to drug therapies, synergism refers to greater than additive effects that are observed when drugs are taken together as opposed to separately. In fact, for HIV,

10   combinations of protease inhibitors and RT inhibitors have demonstrated additive to synergistic effects *in vitro*, which were similar to their *in vivo* effects. A practical consequence of such synergism is that in some cases the dosages of the drugs used in combination may be reduced while maintaining a desired level of therapeutic effect, thus reducing cost, dosage frequency, or the occurrence of undesirable side-effects, or

15   all of these.

As an example, one the most potent combinations in current clinical use consists of two different RT inhibitors in conjunction with an HIV protease inhibitor. In this case, the RT inhibitors, selectively target the activity of HIV reverse transcriptase and serve to reduce the rate at which HIV DNA can be produced from

20   HIV RNA, an event that occurs in the early stages of infection within a given host cell. Meanwhile, the protease inhibitor selectively acts on the HIV protease to interfere with the production of viable virions in the latter stages of infection within a given cell. The use of such combination therapies has become more prevalent, and has been facilitated by the increasing variety of antiretroviral drugs that have been

25   approved for use in humans. There are now at least five nucleoside analogue and non-nucleoside analogue HIV RT inhibitors as well as four HIV protease inhibitors approved for use by the US Food and Drug Administration (FDA). Several more HIV protease inhibitors are likely to be approved within the next year or so.

Although the use of combination drug therapies against HIV has proven to be effective in many patients, the current drug regimens are far from ideal. Adherence to these combination regimes is remarkably difficult in terms of patient compliance, and the drug combinations are quite expensive. Their use has been further hampered

5   because many HIV infected individuals have been on single drug therapies in the past and are currently infected with HIV viruses that are resistant to one or more inhibitors, thereby greatly reducing the effectiveness of the combination drug therapy. As with the RT inhibitors, resistance to protease inhibitors can also occur. Beyond these issues, a number of undesirable side effects, including lipodystrophy syndromes, have

10   surfaced as a consequence of long-term use of protease inhibitors at current dosage levels. These issues make therapy with existing antiviral agents complicated at best and impossible at worst.

Access to a larger variety of antiviral agents mitigates these difficulties to some degree, providing new alternative combinations when a given regimen proves

15   ineffective; furthermore, access to a broader spectrum of selectivity in antiviral agents would greatly increase the number of possible therapeutic combinations. Such a broadened spectrum of selectivity could be achieved if HIV proteins other than RT and the viral protease were the targets of therapeutic drugs. The potential for synergism between drugs with three or more targets should be even greater than is

20   currently found with dual target combinations. Such synergism could lead to greater reductions in dosages with a concomitant reduction in cost and potentially the degree of undesirable side effects. Because one of the major limiting factors in anti-HIV combination therapy is the cost of the antiviral agents, such a dosage reduction could substantially increase the number of patients who could affordably be treated with

25   combination therapy regimens. Further, increasing the number of viral targets would decrease the likelihood that viral strains could emerge that are simultaneously resistant to all therapeutic agents.

Although most clinicians and scientists recognize the need for anti-HIV agents targeted at other HIV proteins to add to current combination therapies, no drugs have

been approved that target the process of HIV integration. As already noted, this stage
of the infectious life cycle is absolutely required for all successive stages and the
productive infection within an individual that gives rise to disease progression. In
principle, if this stage could be targeted with 100% efficiency, further infection of new
5   host cells and disease progression in general could be eliminated. One HIV protein,
the enzyme known as integrase (IN), has been shown to have the minimal activities
necessary for integration. *In vitro*, the enzyme processes HIV DNA for insertion into
double stranded DNA that is found within a host cell's nucleus. Further, IN cleaves
double stranded DNA and facilitates the insertion of the pre-processed HIV DNA into
10   the cleavage site. Finally, IN covalently links the HIV DNA to both cleaved ends of
the host DNA. The remaining step in integration, filling of small gaps in the DNA
sequences that flank the inserted HIV DNA, is probably carried out by host cell DNA
repair mechanisms.

Candidate therapeutic compounds that selectively target the activities of IN
15   have been widely sought. The major classes of IN inhibitors that have been reported
to date include DNA-binding agents, topoisomerase inhibitors, aurintricarboxylic acid
and cosalene analogues, caffeic acid phenylethyl ester (CAPE), curcumin, suramin,
anthraquinones, and bis-catechols and other hydroxylated aromatic compounds. There
have been two chief problems with nearly all of these compounds, both of which
20   stem, in part, from a widespread reliance on *in vitro* assays of IN activity that utilize
purified IN protein. Foremost, selectivity for the IN protein has been difficult to
establish. Even zidovudine and other nucleoside analogues, compounds generally
used to target HIV RT, have been reported to inhibit HIV IN *in vitro* at sufficiently
high concentrations. Aurintricarboxylic acid and related compounds also inhibit RT
25   and other phosphoryltransferase enzymes. Inhibition of IN by DNA-binding agents
and topoisomerase inhibitors, such as doxorubicin, is relatively weak and
nonselective. In virtually all cases, a protective effect of these small molecule IN
inhibitors against HIV infection in live, cultured cells has either been undetectable or
not examined.

There are a few exceptional compounds that have been demonstrated to inhibit IN activity potently *in vitro* and HIV replication in live, cultured cells. Octet oligonucleotide inhibitors of HIV IN have been reported that show both kinds of activity and have been entered into phase I clinical trials. Problems attendant with these compounds include high synthetic costs, low bioavailability, and uncertainty about their mechanism of inhibition. In fact, most evidence supports a mechanism of action prior to integration at the level of viral entry. Another class of compounds that holds promise includes the dicaffeoylquinic acids (DCQAs) and the dicaffeoyltartaric acids (DCTAs). These compounds are similar to bis-catechols except that they are more potent, selective inhibitors of HIV IN catalytic activities *in vitro* and are active in blocking replication of HIV in live, cultured cells at non-toxic concentrations. The compounds disclosed below are all structurally similar to the DCQAs and DCTAs and were developed from studies in which the DCTA L-chicoric acid served as a lead compound.

It is clear that new compounds that have potent anti-HIV activity, both *in vitro* and in live cell studies, and that are selective for inhibition of IN would be valuable as anti-HIV therapeutics or lead compounds for anti-HIV therapeutic development. In cases where such pharmacologic inhibitors of IN show demonstrable synergism with existing drugs (or those currently in development) that target other aspects of the HIV life cycle, including the HIV RT inhibitors and HIV protease inhibitors, significant reductions in cost could result in a wider availability of these treatment regimens among a larger number of patients. Even in the absence of synergism with existing anti-HIV agents, the power of the existing drugs makes it unlikely that any new anti-HIV agent will be introduced into patients unless that agent works in combination with existing anti-HIV therapeutics. Also disclosed herein are data demonstrating that the lead DCTA compound L-chicoric acid can act synergistically in combination with established RT inhibitors, protease inhibitors, and simultaneously with both kinds of these established anti-HIV therapeutics. It is expected that the novel compounds presented herein will show behavior similar to L-chicoric acid. Further it is expected

that these compounds will serve as leads for the development of a greater variety of potent, selective inhibitors of HIV IN.

Brief Summary of Invention

5   The present invention includes a group of novel compounds that are demonstrated to potently and selectively inhibit HIV integrase (IN) activity *in vitro* and to potently inhibit HIV replication in live, cultured cells at non-toxic concentrations. These novel, biologically active IN inhibitors are structural analogues of the selective and potent anti-HIV IN compound, L-chicoric acid. Additionally, the

10   use of IN inhibitors of this class in combination with established anti-HIV therapeutics to form synergistic combinations that inhibit HIV replication in live, cultured cells is demonstrated for the first time. The use of this novel class of IN inhibitors in combination with the established classes of anti-HIV compounds, namely reverse transcriptase (RT) inhibitors and protease inhibitors, to interfere with HIV

15   replication provides a synergistic combination therapy.

In the course of the studies leading up to the present invention, a large number of different analogues of L-chichoric acid were synthesized and investigated in terms of *in vitro* ability to inhibit IN and ability within cell culture to decrease cell death caused by HIV. A number of novel compounds were found that show favorable

20   properties in the assays. Because of their different structural properites some are expected to show superior properties in actual therapeutic regimes. Particularly interesting novel compounds include 2,3-di(3,4-dihydroxydihydroxydihydrocinnamoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-L-tartaric acid,

25   2,3-di-(3,4,5-trihydroxybenzoyl-L-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-L-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-L-serine, bis-dicaffeoyl-L-isoserine and 1,4-dicaffeoyl-L-lysine.

An especially exciting discovery concerns the combination of the integrase inhibitors with other HIV therapeutics such as reverse transcriptase inhibitors and protease inhibitors. Tests of integrase inhibitors with 2',3'-dideoxycytidine, zidovudine and nelfinavir (protease inhibitor) indicated a potent synergy against reverse transcriptase inhibitor resistant virus. The potential benefit from the addition of integrase inhibitors to combination drug therapies is significant.

Brief Description of the Drawings

Fig. 1a shows a structural diagram of compounds number 1, 2, and 3.

Fig. 1b shows a structural diagram of compound number 19.

Fig. 1c shows a structural diagram of compound number 22.

Fig. 2a shows a structural diagram of compound number 25.

Fig. 2b shows a structural diagram of compound number 26.

Fig. 2c shows a structural diagram of compound number 28.

Fig. 3a shows a structural diagram of compound number 35.

Fig. 3b shows a structural diagram of compound number 36.

Fig. 3c shows a structural diagram of compound number 37.

Fig. 4a shows a structural diagram of compound number 38.

Fig. 4b shows a structural diagram of compound number 39.

Fig. 4c shows a structural diagram of compound number 40.

Fig. 4d shows a structural diagram of compound number 41.

Fig. 5 is a histogram showing the anti-HIV activity of several established anti-HIV therapeutics and L-CCA against 4 different HIV molecular clones.

Fig. 6 is a graph of the anti-HIV activity, as measured by RT release, of various drug combination regimens against HIV_{LAI}. Each point is the mean of triplicate infections; error bars indicate standard deviations.

Fig. 7 is a graph of the anti-HIV activity, as measured by RT release, of various drug combination regimens against HIV_{LAI}. Each point is the mean of triplicate infections; error bars indicate standard deviations.

Fig. 8 is a graph of the anti-HIV activity, as measured by RT release, of various drug combination regimens against the clinically isolated strain HIV_{R45}. Each point is the mean of triplicate infections; error bars indicate standard deviations.

Fig. 9 is a graph of the anti-HIV activity, as measured by RT release, of various drug combination regimens against the clinically isolated strain HIV_{R19}. Each point is the mean of triplicate infections; error bars indicate standard deviations.

Fig 10 is a diagram of Scheme 1 showing the steps in the chemical synthesis of some of the compounds disclosed in the present invention. Abbreviations of compounds are as follows: **OM** = O-methoxycarbonyl = -OCOOMe; **DPM** = diphenylmethyl = $-CHPh_2$; **CAF** = caffeoyl = $-COCH=CH-[3,4-(OH)_2-phenyl]$; **BMC**= bismethoxycarbonylcaffeoyl = $-COCH=CH-[3,4-(OM)_2-phenyl]$. Components of procedures are abbreviated: [A]: ClCOOMe; [B]: Na_2CO_3; [C]: Ph_2CHN_2; [D]: HOAc; [E]: RCOCl; [F]: $RCOCl/R_3N$; [G]: L-tartaric acid; [H]: $[COCl]_2$; [I]: $SOCl_2$.

Fig 11 is a diagram of Scheme 2 showing the steps in the chemical synthesis of some of the compounds disclosed in the present invention. Abbreviations of compounds are as follows: **OM** = O-methoxycarbonyl = -OCOOMe; **DPM** = diphenylmethyl = $-CHPh_2$; **CAF** = caffeoyl = $-COCH=CH-[3,4-(OH)_2-phenyl]$; **BMC**= bismethoxycarbonylcaffeoyl = $-COCH=CH-[3,4-(OM)_2-phenyl]$. Components of procedures are abbreviated: [A]: ClCOOMe; [B]: Na_2CO_3; [C]: Ph_2CHN_2; [D]: HOAc; [E]: RCOCl; [F]: $RCOCl/R_3N$; [G]: L-tartaric acid; [H]: $[COCl]_2$; [I]: $SOCl_2$.

Fig 12 is a diagram of Scheme 3 showing the steps in the chemical synthesis of some of the compounds disclosed in the present invention. Abbreviations of compounds are as follows: **OM** = O-methoxycarbonyl = -OCOOMe; **DPM** = diphenylmethyl = -CHPh$_2$; **CAF** = caffeoyl = -COCH=CH-[3,4-(OH)$_2$-phenyl]; **BMC**= bismethoxycarbonylcaffeoyl = -COCH=CH-[3,4-(OM)$_2$-phenyl]. Components of procedures are abbreviated: [A]: ClCOOMe; [B]: Na$_2$CO$_3$; [C]: Ph$_2$CHN$_2$; [D]: HOAc; [E]: RCOCl; [F]: RCOCl/R$_3$N; [G]: L-tartaric acid; [H]: [COCl]$_2$; [I]: SOCl$_2$.

Fig 13 is a diagram of Scheme 4 showing the steps in the chemical synthesis of some of the compounds disclosed in the present invention. Abbreviations of compounds are as follows: **OM** = O-methoxycarbonyl = -OCOOMe; **DPM** = diphenylmethyl = -CHPh$_2$; **CAF** = caffeoyl = -COCH=CH-[3,4-(OH)$_2$-phenyl]; **BMC**= bismethoxycarbonylcaffeoyl = -COCH=CH-[3,4-(OM)$_2$-phenyl]. Components of procedures are abbreviated: [A]: ClCOOMe; [B]: Na$_2$CO$_3$; [C]: Ph$_2$CHN$_2$; [D]: HOAc; [E]: RCOCl; [F]: RCOCl/R$_3$N; [G]: L-tartaric acid; [H]: [COCl]$_2$; [I]: SOCl$_2$.

Fig 14 is a graph of HIV$_{NL4-3}$ passaged in the presence (squares) or absence (circles) of increasing concentrations of L-chicoric acid. Each point is the mean of triplicate samples; bars are one standard deviation.

Fig. 15 is a schematic diagram of the cloning strategy used to analyze mutations in HIV IN.

Fig. 16a is a graph showing the relative resistance of 4 molecular clones of HIV to the RT inhibitor zidovudine.

Fig. 16b is a graph showing the relative resistance of 4 molecular clones of HIV to the IN inhibitor L-chicoric acid.

The invention and its various embodiments may now be understood by turning to the following Detailed Description of the Preferred Embodiments.

Detailed Description of the Preferred Embodiments

The present invention generally related to integrase inhibitors having the general structural formula (formula(I)):

5

$$
\begin{array}{c}
R \\
| \\
R_2 - C - R_1 \\
| \\
(CH_2)n \\
| \\
R_4 - C - R_3 \\
| \\
R_5
\end{array}
$$

10

wherein,

R_1 and R_3 are selected from hydrogen, OR_6,, NR_6 and aralkyl groups, optionally

15   substituted with between one and three substituents selected from hydroxyl, halo, lower alkoxy, lower alkylcarbonyloxy and lower alkoxycarbonyloxy groups;

R and R_5 are selected from hydrogen, $COOR_7$ and $CONHR_7$;

R_2 and R_4 are hydrogen or may combine with each other to form a cycloalkyl ring or with R_1 and R_4, respectively, to form aromatic rings optionally substituted with from

20   one to three substituents selected from OR_6 and NR_6 groups;

R_6 is selected from

25

$$
\underset{\text{-C-X}}{\overset{\overset{\displaystyle O}{\|}}{}} \!\!\!\!\!\!\! \diagdown\!\!\!\!\diagup^{(R_8)m}_{Y}
$$

where,

X is a saturated or unsaturated, acyclic or cyclic, straight or branched, chiral or achiral hydrocarbyl group with from 0 to 10 carbon atoms, and

Y is selected from CH=CH, n=CH, CH=N, O, S, or NR_7. n is between 0 and 4, and m is between 0 and 3.

5   R_7 is selected from hydrogen, alkyl and aralkyl groups;

R_8 is selected from hydrogen, hydroxy, halo, lower alkoxy, lower alkycarbonyloxy and lower alkoxycarbonyloxy or a cyclic carbonate group when the hydroxy groups are on adjacent carbons;

Additionally, when R and R_5 are $COOR_7$ or $CONHR_7$, the groups R_1, R_2 and

10   R_3, R_4 may combine to form an arylidene group, optionally substituted from 1 to 3 substituents selected from hydroxy, halo, lower alkoxy, lower alkycarbonyloxy and lower alkoxycarbonyloxy.

A preferred group of compounds of formula (1) is that wherein, R and R_5 are $COOR_7$ and $CONR_7R_9$; R_2 and R_4 are hydrogens; R_1 and R_3 are aralkyl or R_1, R_2 and

15   R_3, R_4 may combine to form an arylidene group, optionally substituted with up to 3 hydroxy, alkylcarbonyloxy or alkoxycarbonyloxy groups or OR_6 or NR_6; R_6 is

$$ \overset{O}{\underset{}{\underset{\|}{-C}}}-X-\left\langle \overset{(R_8)m}{\underset{Y}{}}\right. $$

20

where, X is saturated or unsaturated hydrocarbyl group with from 0 to 4 carbon atoms, Y is CH=CH, CH=N, N=CH, O, S or NR_7; R_7 and R_9 are same or different and may be hydrogen, lower alkyl and alkenyl or aralkyl or R_7 and R_9 may combine to form a

25   heterocyclic ring, optionally substituted with one or more lower alkyl with from 1 to 5 carbon atoms, aralkyl and hydroxy groups; R_8 represents up to 3 hydroxy, alkylcarbonyloxy or alkoxycarbonyloxy groups and n is 0.

5   Examples include:

2,3-di-3-(3,4-dihydroxyphenyl)-2-propenoyl L-tartaric acid *(Dicaffeoyl-L-tartaric acid)*

2,3-di-3-(3,4-dihydroxyphenyl)-2-propenoyl D-tartaric acid *(Dicaffeoyl-D-tartaric*

10   *acid)*

2,3-di-3-(3,4-dihydroxyphenyl)-2-propenoyl meso-tartaric acid *(Dicaffeoyl-meso-tartaric acid)*

2,3-di-3-(3,4-dihydroxyphenyl)propanoyl L-tartaric acid *[Bis-2,3-(3,4-dihydroxydihydrocinnamoyl)-L-tartaric acid]*

15   2,3-di-3,4-dihydroxybenzoyl L-tartaric acid *[Bis-(3,4-dihydroxybenzoyl) L-tartaric acid]*

2,3-di-(3,4-dihydroxyphenyl)acetyl L-tartaric acid *[Bis-(3,4-dihydroxyphenylacetyl) L-tartaric acid]*

2,3-di-3,4,5-trihydroxybenzoyl L-tartaric acid *(Digalloyl-L-tartaric acid)*

20   2,3-di-2,3-dihydroxybenzoyl L-tartaric acid *[Bis-(2,3-dihydroxybenzoyl) L-tartaric acid]*

2,3-di-3,4-dihydroxybenzylidene succinic acid *(di-3,4-dihydroxybenzylidene succinic acid)*

2,3-di-3,4-dihydroxybenzyl succinic acid

25   and esters and pharmaceutically acceptable salts thereof.

Yet another preferred group of compounds of formula (1) is that wherein, R,

R_2, R_4 and R_5 are hydrogens or R_2 and R_4 may combine to form a cycloalkyl ring or

with R_1 and R_2 may form an aromatic ring substituted with up to 3 OR_6 or NR_6

30   groups; R_1 and R_3 are OR_6 or NR_6, where R_6, X, Y, R_8 and m are described as earlier

and n is 0-4.

Examples include:

35   1,2-Dihydroxyethyl 3-(3,4-dihydroxyphenyl)-2-propenoate *(1,2-Dicaffeoylethanediol)*

1,3-Dihydroxypropyl 3-(3,4-dihydroxyphenyl)-2-propenoate *(1,3-Dicaffeoylpropanediol)*

1,4-Dihydroxybutyl 3-(3,4-dihydroxyphenyl)-2-propenoate *(1,4-Dicaffeoylbutanediol)*

40   trans-1,4-Dihydroxycyclohexyl 3-(3,4-dihydroxyphenyl)-2-propenoate *(1,4-trans-Dicaffeoylcyclohexanediol)*

cis-1,4-Dihydroxycyclohexyl 3-(3,4-dihydroxyphenyl)-2-propenoate *(1,4-cis-Dicaffeoylcyclohexanediol)*
trans-1,3-Dihydroxycyclohexyl 3-(3,4-dihydroxyphenyl)-2-propenoate *(1,3-trans-Dicaffeoylcyclohexanediol)*

5   cis-1,3-Dihydroxycyclohexyl 3-(3,4-dihydroxyphenyl)-2-propenoate *(1,3-cis-Dicaffeoylcyclohexanediol)*
trans-1,2-Dihydroxycyclohexyl 3-(3,4-dihydroxyphenyl)-2-propenoate *(1,2-trans-Dicaffeoylcyclohexanediol)*
cis-1,2-Dihydroxycyclohexyl 3-(3,4-dihydroxyphenyl)-2-propenoate *(1,2-cis-*

10   *Dicaffeoylcyclohexanediol)*
1-Carboxyphenyl-3,5-di-3-(3,4-dihydroxyphenyl)-2-propenoate *(3,5-Dicaffeoyl benzoic acid)*
1-Carboxyphenyl-3,4-di-3-(3,4-dihydroxyphenyl)-2-propenoate *(bis-3,4-Dicaffeoyl benzoic acid)*

15   1-Carboxyphenyl-3,4-di-3-(3,4-dihydroxyphenyl)-2-propenamide *(bis-3,4-Dicaffeoyl benzoic acid)*
and esters and pharmaceutically acceptable salts thereof.

Yet another preferred group of compounds of formula (1) is that wherein, R is

20     $COOR_7$ and $CONR_7R_9$; R_1, R_4 and R_5 are hydrogens; R_2 and R_3 are OR_6 and NR_6; R_6,

X, Y, R_7, R_8, R_9 and m are as defined earlier and n is 0-4.

Examples include:

25   1-Carboxy-2-[3-(3,4-dihydroxyphenyl)-2-propenoyl]amino- 3-propyl[3-(3,4-dihydroxyphenyl)-2-propenoate *(2,3-Dicaffeoyl-L-serine)*
1-Carboxy-3-[3-(3,4-dihydroxyphenyl)-2-propenoylamino]- 2-propyl [3-(3,4-dihydroxyphenyl)-2-propenoate *(bis-Dicaffeoyl-L-isoserine)*
2,3-Di-[3-(3,4-dihydroxyphenyl)-2-propenoyl]aminopropanoic acid *(2,3-*

30   *Dicaffeoyldiamidopropionic acid)*
1-Carboxypropyl di-2,3-[3-(3,4-dihydroxyphenyl)-2-propenoate] *(1,2-Dicaffeoyl-L-glyceric acid)*
2,6-Di-[3-(3,4-dihydroxyphenyl)-2-propenoyl]aminohexanoic acid *(1,4-Dicaffeoyl-L-lysine)*

35

It will be readily appreciated by those of skill in the art that certain compounds

represented by the above formula may exhibit optical and geometric isomerism.

However, when no designation of isomers is specified with respect to the compounds

of the present invention, it is to be understood that all possible stereoisomers (R, S), geometric isomers (E, Z) and racemates are included within the invention.

In addition, certain of the compounds that fall within the described bounds of the present invention may form salts with organic and inorganic bases, and it is specifically contemplated that all such salts, in particular physiologically acceptable salts, are included within the present invention.

The chemical structures of the compounds are illustrated in Figs. 1-4. In Fig. 1a, the D- and meso- isomers of L-chicoric acid are identical in this illustrative format. Pharmacological data about the compounds that constitute the invention can be found in Table 1. Table 1 lists the compounds by name, with a chemical identification number keyed to the drawings, LD_5, ED_{50}, and IC_{50}. The first compound in Table 1, L-chicoric acid, a previously described DCTA, is included for reference. LD_5, the 5% lethal dose, is a measure of the toxicity of compound to living, cultured cells. It is the concentration at which cell growth is inhibited by 5%. This represents a truly non-toxic dose as it is within one standard deviation of the growth observed for cells cultured in the absence of the compound. ED_{50}, the 50% effective dose, is the concentration of compound that inhibits HIV-induced cell death by 50% with respect to control HIV infections of cells monitored in the absence of compound. IC_{50}, the 50% inhibitory dose, is the concentration of compound that is observed to inhibit purified HIV IN activity *in vitro* in an assay of IN dependent disintegration. Most simply understood, disintegration is a term used to refer to the reverse of integration.

The biological role of IN is to catalyze the insertion of viral DNA into the double-stranded, nuclear DNA of a host cell, while leaving flanking free viral 5' ends. However, because IN is a true enzyme, it can also catalyze the reverse reaction, namely, excision of viral-like DNA from a double-stranded DNA substrate where free viral-like 5' ends occur. The use of an appropriately designed DNA substrate allows for IN dependent disintegration to be measured. Not all of the possible enzymatic functions of IN are completely understood; therefore, it is not warranted to state that

in vitro measurement of disintegration inhibition is a complete measure of IN inhibition. Nonetheless, the compounds presented herein generally show a strong correlation between *in vitro* potency as measured by inhibition of disintegration, and biological potency as measured by inhibition of HIV replication in living, cultured cells. Furthermore, for those compounds in which other measures of IN activity (3'-end processing and strand transfer) have been measured there has been a 1:1 correlation between inhibition of these steps and disintegration.

All of the compounds included in Table 1 inhibit HIV IN dependent disintegration by 90% or more when tested at 25 μM concentration. This is an *in vitro* measure of potency. The IC_{50} is also a measure of *in vitro* potency. This value is significantly smaller than the LD_5 for all the compounds suggesting that each of the compounds may serve to inhibit HIV replication in cells through HIV IN inhibition at non-toxic concentrations. Biological potency can be more directly assessed by reference to the LD_5 and ED_{50}. In all cases, the ED_{50} is less than or equal to the LD_5, thus, with these compounds a 50% effective dose is expected to cause little or no significant cell toxicity. In general, the wider the margin of LD_5 over ED_{50}, the greater the concentration of the compound that can be used without danger of causing cell death.

Table 1

Compound Name	ID number	LD_5 (μM)	ED_{50} (μM)	IC_{50} (μM)
L-chicoric acid	1	264	4.2	0.18
D-chicoric acid	2	115	6.3	0.07
m-chicoric acid	3	373	4.2	0.08
1,2-dicaffeoyl-L-glyceric acid	19	145	2.3	0.520
Bis-(3,4-dihydoxydihydrocinnamoyl)-	22	>263	8.4	2.38

Compound Name	ID number	LD$_5$ (μM)	ED$_{50}$ (μM)	IC$_{50}$ (μM)
L-tartaric acid				
Digalloyl-L-tartaric acid	25	2.7	0.66	0.97
Bis-(3,4-dihydroxybenzoyl)-L-tartaric acid	26	90	0.95	0.43
Bis-(3,4-dihydroxyphenylacetyl)-L-tartaric acid	28	70	35	0.88
2-3-dicaffeoyldiamidopropionic acid	35	50	70	0.570
Bis-3,4-dicaffeoyldiamidobenzoic acid	36	47	4.6	0.734
Di-3,4-dihydroxybenzylidene succinic acid	37	35	8.7	2.19
Di-3,4-dihydrodihydroxybenzylidine succinic acid	38	69	4.4	0.858
2,3-dicaffeoyl-L-serine	39	29	2.5	0.120
Bis-dicaffeoyl-L-isoserine	40	175	3.0	0.195
1,4-dicaffeoyl-L-lysine	41	29.2	3.7	2.23

Many of these compounds appear to selectively inhibit HIV IN as the means by which they inhibit HIV replication in living, cultured cells. This is most strongly indicated for compounds 1, 22, 25, 26, and 28 which all show reduced efficacy against

5   a molecular clone of HIV, HIV$_{NL4-3clone1-D4}$, that was generated by selection for resistance to L-chicoric acid (compound 1) and was shown to bear a single point mutation in its gene for IN. The single point mutation results in the substitution of a serine amino-acid residue for the normally occurring glycine amino-acid residue at position 140 in the primary sequence of HIV IN. The demonstration that a single

10   amino-acid substitution at this position within IN confers resistance to L-chicoric acid

is strong evidence that the principle target for the anti-HIV activity of L-chicoric acid
is IN. Likewise, if this mutation confers marked resistance to other anti-HIV
compounds the evidence is equally strong that IN is also a target of these compounds.
Referring to Table 2 which shows the anti-HIV activity of L-chicoric acid analogues
against the L-chicoric acid resistant clone, $HIV-1_{NL4-3clone1-D4}$, the ED_{50} for each of the
noted compounds is significantly increased when measured against the resistant
molecular clone $HIV_{NL4-3clone1-D4}$ as compared to against the parental non-resistant strain
HIV_{NL4-3}.

Table 2

Compound	ED_{50} (in µM)		Fold Change
	HIV_{NL4-3}[a]	$HIV_{NL4-3clone1-D4}$[b]	
1	0.78	61.25	78
22	7.8	31.25	4
25	0.29	31.25	107
26	0.82	52.5	64
28	15.6	62.5	4

[a]The anti-HIV activity of each compound was tested against the infectious molecular
clone $HIV-1_{NL4-3}$. The ED_{50} is expressed as the mean of triplicate infections.

[b]The anti-HIV activity of each compound was measured against L-chicoric acid-resistant
molecular clone $HIV-1_{NL4-3clone1-D4}$. The results are expressed as the mean of triplicate
infections.

Since combination drug therapies are now the standard of care in the medical
treatment of HIV infection, any new therapeutics and therapeutic leads should work in
combination with existing classes of anti-HIV drugs. The therapeutic effects of drugs,
when used in combination, can generally be described as falling into one of three
categories. In the best case, drugs administered in combination can act synergistically,

having net therapeutic effects that are greater than the sum of the effects observed
when the drugs are administered individually. When drug combinations appear to act
with equivalent net therapeutic effects as the sum of the effects when administered
individually, the drugs are said to act additively. In the worst case, drugs can act

5   counter-productively, resulting in reduced efficacy when used in combination; this is
referred to as antagonism. In general, for the use a drug combination to be warranted,
additive to synergistic effects should be demonstrable. Demonstration of such effects
in vitro is a first indication that such effects can occur in a medically prescribed
therapeutic regimen. As noted, combinations of protease inhibitors and RT inhibitors

10   have previously demonstrated additive to synergistic anti-HIV effects in vitro, which
have been similar to their in vivo effects. Similarly, now such anti-HIV activity has
been demonstrated for established anti-HIV agents in conjunction with the lead IN
inhibitor L-chicoric acid (L-CCA, compound 1). In almost all circumstances tested, L-
chicoric acid has acted either synergistically or additively with RT inhibitors and/or

15   protease inhibitors to inhibit HIV replication.

      Pairwise combinations of L-CCA with individual RT inhibitors or a protease
inhibitor were tested in living cell assays against three different molecular clones of
HIV. The molecular clones were $HIV_{NL4-3\ clone\ 7-1}$, which has silent mutations in the
gene for IN and shows an increased susceptibility to the RT inhibitor dideoxycytidine

20   (DDC), $HIV_{NL4-3\ M185V}$, which has a methionine to valine mutation in the gene for RT
and shows partial resistance to DDC and another RT inhibitor 2',3'-dideoxyinosine
(DDI), and $HIV_{NL4-3\ JF26/A7}$, which has numerous mutations in the gene for RT and is
highly resistant to the RT inhibitor zidovudine (ZDV). For each of these HIV clones,
the ED_{50} was determined for the anti-HIV compounds ZDV, DDC, DDI, the protease

25   inhibitor (PI) Nelfinavir (provided by Agouron Pharmaceuticals, San Diego), and L-
CCA. This is shown in Fig. 5. The results of mixed dose effect analyses using the
method of Chou and Talalay (Adv. Enzyme Regu. 22:27-55(1984)) are summarized in
Table 3 The quantitative data behind this summary is described in the detailed
description of the preferred embodiments and in Tables 4-6 . Table 4 shows the data

for the DDC plus L-chicoric acid combination. Table 5 shows the results for Nelfinavir plus L-chicoric acid. While Table 6 shows the results for Zidovudine plus L-chicoric acid. The principle conclusion from these experiments is that in living cell assays of anti-HIV replication, L-CCA shows synergistic effects when paired with the RT inhibitor DDC and when paired with the protease inhibitor Nelfinavir, against all three molecular clones of HIV. L-CCA also shows synergism when paired with the RT inhibitor ZDV against two of the three HIV clones.

Table 3

Resistance	HIV	ZDV + L-CCA	DDC + L-CCA	L-CCA + PI
None	clone7-1	SI Ant	S	S
DDC	M184V	MS	SS	S
ZDV	JF26/A7	S	SS	MS

DDC = dideoxycytidine
ZDV = zidovudine
L-CCA = L-chicoric acid
PI = protease inhibitor (nelfinavir)
MS = moderate synergism: CI = 0.7-0.85
S = synergy CI = 0.3-0.7
SS = Strong Synergism: CI = 0.1-0.3
VSS = Very Strong Synergism: CI < 0.1
A = additivity: CI = 0.9-1.1
SI Ant = slight antagonism: CI = 1-2.0

Table 4

Virus (HIV-1)	Fa* (protection)	CI†	DDC (nM)	L-CCA (nM)
NL4-3$_{clone7-1}$	0.2	1.144 (0.35)	12.4	148.3
	0.4	0.726 (0.18)	21.1	253.1
	0.6	0.578 (0.14)	32.8	393.7
	0.8	0.493 (0.13)	56.0	672.0

Virus (HIV-1)	Fa* (protection)	CI†	DDC (nM)	L-CCA (nM)
	0.9	0.456 (0.14)	87.1	1046
NL4-3$_{cloneM184V}$	0.2	0.576 (0.27)	21.6	64.8
	0.4	0.358 (0.08)	43.2	129.7
	0.6	0.283 (0.05)	76.8	230.3
	0.8	0.249 (0.05)	153.7	461.2
	0.9	0.242 (0.06)	273	819
NL4-3$_{cloneJF26/A7}$	0.2	2.367 (1.6)	13.0	78.1
	0.4	0.395 (0.1)	23.8	142.8
	0.6	0.214 (0.06)	39.2	235.3
	0.8	0.177 (0.05)	71.8	430.5
	0.9	0.165 (0.09)	118	709

*Fa is the fraction affected (i.e. Fa x 100 is the percent protection). Values for 20%, 40%, 60%, 80%, and 90% are indicated.

†Is the combination index. It was calculated using CalcuSyn for Windows and is one representative experiment from a minimum of three. Each experimental value

Table 5

Virus (HIV-1)	Fa* (protection)	CI†	Nelfinavir (nM)	L-CCA (nM)
NL4-3$_{clone7-1}$	0.2	0.906 (0.29)	2.9	163.6
	0.4	0.472 (0.12)	4.9	279.6
	0.6	0.329 (0.08)	7.6	435.4
	0.8	0.26 (0.08)	13.1	743.9
	0.9	0.239 (0.09)	20.3	1158
NL4-3$_{cloneM184V}$	0.2	1.81 (0.65)	2.5	144

Virus (HIV-1)	Fa* (protection)	CI†	Nelfinavir (nM)	L-CCA (nM)
	0.4	0.91 (0.21)	4.7	269.2
	0.6	0.536 (0.12)	7.9	451.5
	0.8	0.293 (0.08)	14.8	844.1
	0.9	0.183 (0.07)	24.8	1416
NL4-3cloneJF26/A7	0.2	7.982 (5.3)	4.6	264.5
	0.4	1.138 (0.25)	7.0	401.8
	0.6	0.577 (0.13)	10.0	567.8
	0.8	0.444 (0.11)	15.1	862.5
	0.9	0.388 (0.11)	21.3	1219

*Fa is the fraction affected (i.e. Fa x 100 is the percent protection). Values for 20%, 40%, 60%, 80%, and 90% are indicated.

†Is the combination index. It was calculated using CalcuSyn for Windows and is one representative experiment from a minimum of three. Each experimental value was determined in triplicate. Values in parenthesis are 1.96 x SD as estimated in the computer program.

Table 6

Virus (HIV-1)	Fa* (protection)	CI†	Zidovudine (nM)	L-CCA (nM)
NL4-3clone7-1	0.2	0.898 (0.37)	2.7	67.2
	0.4	1.023 (0.34)	8.7	217
	0.6	1.197 (0.34)	22.9	571.8
	0.8	1.508 (0.44)	73.8	1845
	0.9	1.865 (0.67)	194	4861
NL4-3cloneM184V	0.2	0.803 (0.39)	4.9	63.2
	0.4	0.508 (0.17)	10.2	132.7
	0.6	0.373 (0.1)	18.9	245.2

Virus (HIV-1)	Fa* (protection)	CI'	Zidovudine (nM)	L-CCA (nM)
	0.8	0.272 (0.07)	39.6	514.8
	0.9	0.217 (0.07)	73	951
NL4-3$_{cloneJF26/A7}$	0.2	12.6 (8.9)	150.2	450.6
	0.4	1.119 (0.36)	259.8	779.4
	0.6	0.157 (0.08)	409	1226
	0.8	0.017 (0.04)	707	2120
	0.9	0.003 (0.02)	1112	3336

*Fa is the fraction affected (i.e. Fa x 100 is the percent protection). Values for 20%, 40%, 60%, 80%, and 90% are indicated.

'Is the combination index. It was calculated using CalcuSyn for Windows and is one representative experiment from a minimum of three. Each experimental value was determined in triplicate. Values in parenthesis are 1.96 x SD as estimated in the computer program.

A study has also been conducted that shows synergistic activity of L-CCA against HIV when included in a triple combination of anti-HIV agents. As shown in Fig. 6 against the tissue adapted strain of HIV, HIV$_{LAI}$, the addition of L-CCA to a combination of zidovdine and the protease inhibitor AG1350 (provided by Agouron Pharamceuticals, San Diego), allowed the dosages of each of the established inhibitors to be reduced by 33% to achieve equivalent anti-HIV replication effects in living, cultured cells. Furthermore, as shown in Fig. 7, when all compounds were administered at constant dose, the triple combination of L-CCA plus ziduvodine plus protease inhibitor showed greater anti-HIV$_{LAI}$ replication potency than any of the compounds individually or in pairwise combination. Figs. 8 and 9 show that similar results were obtained against two clinically isolated HIV strains, HIV$_{R45}$ and HIV$_{R19}$. Against both strains, a triple combination including L-CCA, zidovudine and protease inhibitor, had greater anti-HIV replication activity than a dual combination of ZDV

and protease inhibitor. The measurements that yielded these results are more completely described in the detailed description of the preferred embodiments.

The lead compound L-CCA has demonstrable compatibility and additive to synergistic effects with compounds from the established classes of anti-HIV agents.
5   The novel, analogue compounds of L-CCA presented generally show equivalent or improved anti-HIV effects consistent with similar potency and selectivity shown when evaluated individually. The translation of such *in vitro* synergistic effects to *in vivo* effects has already occurred with combinations of established anti-HIV compounds. The addition of this new class, as represented by the novel compounds introduced
10 here, of IN inhibitors with demonstrable anti-HIV replication activity provides a new avenue for the pursuit and development of clinically valuable anti-HIV therapeutics.

Each novel compound was pursued using the following steps: 1) chemical synthesis, 2) chemical characterization, 3) biological characterization with living cells, including a) determination of LD_5 by cell toxicity assay, b) determination of ED_{50} by
15 anti-HIV assay, and c) assessment of selectivity against IN by ED_{50} determination against the L-chicoric acid (L-CCA) resistant strain, $HIV_{NL4-3clone1-D4}$, 4) biochemical characterization, i.e., determination of IC_{50} with the disintegration assay, and 5) determination of pharmacological compatibility of anti-HIV activity when used in combination with members of the established classes of anti-HIV therapeutics, i.e.,
20 determination of capacity to act synergistically. This entire course of assessment is not presented for all compounds. Representative examples of these steps and relevant data illustrated by figures and tables are presented below.

Synthesis

In an effort to develop more potent and selective inhibitors of HIV-1 IN,
25 analogues of the DCTA, L-CCA, were synthesized. Exemplary synthetic schemes for a few of these compounds are shown in Figs. 1-4 and described below. The length of the side chains, spatial arrangement of the phenolic hydroxyl groups, size and structure of the central molecular core structure, and number of free carboxyl groups

were all varied. The effects of these changes were assayed against HIV-1 IN in the disintegration reaction as well as against HIV-1 replication and cell growth in tissue culture.

The synthetic schemes which are illustrated in Figs. 10-13 are briefly

5   described as follows:

L-(1), D-(2)- and meso-(3) DCTA were synthesized by acylation of the bis(di-phenylmethyl) tartrates (1a, 2a and 3a) with the protected caffeoyl chloride (35a) to give the fully-blocked compounds (20, 2b and 3b) from which the phenol and carboxyl blocking groups were sequentially removed via (21, 2c and 3c) (Fig. 10,

10   Scheme 1).

A compound with a single carboxyl group, dicaffeoylglyceric acid (19) was prepared by acylation with (35a) and deprotection via 19a (Fig. 11, Scheme 2).

To determine the effect on bioactivity of the group linking the catechol and tartaric acid moieties of 1, analogues were prepared with the CH=CH replaced by two

15   (22), one (28) or zero (26) methylene groups. Direct acylation of L-tartaric acid with the acid chlorides of the phenol protected acids 22a, 28a and 26a gave 22b, 28b and 26b from which the phenol blocking groups were removed (Fig. 12, Scheme 3).

The significance for bioactivity of the number and position of the phenol groups was determined in the benzoic acid series (Fig. 13, Scheme 4). An analogue

20   with three (25) phenolic hydroxyl groups was synthesized by acylation of the diester of L-tartaric acid 1a with the acid chloride of the phenol-protected acid 25a followed by removal of the appropriate blocking groups.

Chemical Procedures:

Detailed synthetic procedures and chemical characterizations, as referred to in

25   Figs. 10-13, are described as follows.

General. All melting points were measured on a Mel-Temp apparatus and are corrected. Elemental analyses were performed by M-H-W laboratories of Phoenix, AZ. Mass spectrometry (MS) analyses were obtained on a HP-5989A instrument at 70 eV in the EI mode with GC sampling unless otherwise noted as DIP (direct insertion probe). Selected peaks are reported as m/z (rel.int.) including all (except isotope peaks) with m/z>100 and relative intensity >25. HRFABMS were performed at the Washington University Resource for Biomedical and Bio-Organic Mass Spectrometry, St. Louis, MO. NMR spectra were obtained on a Varian XL-300 instrument at 299.936 (^{1}H) or 75.427 (^{13}C) unless otherwise noted in the indicated solvent (D=DMSO-d$_6$, C=CDCl$_3$, M=CD$_3$OD) and are reported in order as: ppm downfield from TMS at δ=0, multiplicity (s, d, dd, m, bs), observed couplings J in Hz and relative # of H's. APT spectra results are expressed as d=C or CH$_2$, u=CH or CH$_3$. HPLC used a C-18-10μm, 250mm × 4.6mm analytical column or a C18-10μm, 250 × 22mm preparative column eluted with either methanol-water or acetonitrile-water mixtures containing 1% acetic acid with UV detection at 254 nm. The following general synthetic procedures refer to both Schemes 1-4 and the description of the preparation of the specific compounds that follows. No attempt was made to optimize yields.

Procedure A, Carboxymethylation of Phenols: A solution of the phenolic acid in 2.2 eq 1N NaOH was cooled to 0°C and 3.5 eq methyl chloroformate was added drop-wise with stirring. The precipitate was collected by filtration, washed with deionized water, air dried and recrystallized to give the blocked phenolic acid.

Procedure B, Removal of Carboxymethyl Groups: The carboxymethylated phenol was dissolved in tetrahydrofuran (THF) and hydrolyzed with 2% Na$_2$CO$_3$ with enough methanol for homogeneity at room temperature, under N$_2$ for 5-7hr. The reaction mixture was acidified to pH=1-2 with 10N HCl, extracted with ether, the ether evaporated and the residue purified by chromatography on silica gel, if necessary.

Procedure C, Formation of Diphenylmethyl Esters: A solution of 1.25eq diphenyldiazomethane per COOH group in chloroform was added to the carboxylic acid in MeOH-CHCl₃. The mixture was stirred at room temperature until the red color disappeared, washed successively with 1N HCl, saturated NaHCO₃ and H₂O. The
5   organic layer was dried with Na₂SO₄ and evaporated on a Rotovap to afford the diphenylmethyl ester which was recrystallized if necessary.

Procedure D, Hydrolysis of Diphenylmethyl Esters: The diphenylmethyl esters were deprotected in refluxing 70% acetic acid under N₂ for 4 hours. The solvent was removed by lyophilization and the residue purified by chromatography on
10   Sephadex LH-20.

Procedure E, Direct Acylation of Alcohol Groups: The alcohol was reacted with a slight excess of the acid chloride without solvent in an oil bath at 130-140 °C for 15 min and the residue chromatographed on silica gel.

Procedure F, Solution Acylation of Alcohol Groups: The acyl chloride was
15   reacted with the alcohol in anhydrous benzene with pyridine or triethylamine as a catalyst for 2.5hr at room temperature. The reaction mixture was successively washed with 1N HCl, saturated NaHCO₃ and water and the organic layer evaporated to give the ester which was purified on a silica gel column.

Procedure G, Direct Acylation of L-Tartaric Acid: A modification of
20   Scarpati's method (*Tetrahedron* 4:43-48 (1958)) involves heating L-tartaric acid with an excess of an acyl chloride in an oil bath at 135-160°C for 10-30min followed by hydrolysis of the intermediate anhydride with 80% HOAc on a steam bath for 30 min. The residue from removal of the solvent below 40°C under reduced pressure was partitioned between water and ether and the latter dried and evaporated to give a crude
25   product which was purified by chromatography on silica gel or Sephadex LH-20.

Procedure H, Formation of Acyl Chlorides with Oxalyl Chloride: A
solution of the acid in excess oxalyl chloride was stirred with a 25-fold excess of

oxalyl chloride at room temperature for one hour, the excess reagent removed on a Rotovap and the acid chloride used immediately without purification.

Procedure I, Formation of Acyl Chlorides with Thionyl Chloride: A solution of the acid in excess thionyl chloride was heated (NaOH trap) in an oil bath at
5   80-90°C until HCl evolution ceased. Removal of the thionyl chloride on a Rotovap gave the acid chloride used immediately without purification.

Specific Syntheses and Chemical Characterizations:

Dicaffeoyl-L-tartaric acid (L-chicoric acid, L-DTCA or L-CCA) (1). L-Tartaric acid was converted by Procedure C to **bis(diphenylmethyl) L-tartrate (1a)**
10   as a white powder, mp=107-108°C; ^{1}H NMR (C): 7.24-7.32 (m, 20H), 6.98 (s, 2H), 4.75 (s, 2H); ^{13}C (C): 170.7, 139.0, 138.9, 128.6, 128.5, 128.4, 128.1, 127.6, 126.9, 79.2, 72.3; DIP/MS: 315 (2), 183 (33), 167 (100), 165 (43). Reaction of **1a** with **35a** via Procedure F gave **bis(diphenylmethyl) bis[di(methoxycarbonyl)caffeoyl]-L-tartrate (20)**, mp=62-64°C; ^{1}H NMR (C): 7.50 (d, 16.0, 2H), 7.10-7.38 (m, 20H),
15   6.94 (s, 2H), 6.16 (d, 16.0, 2H), 6.04 (s, 2H), 3.93 (s, 6H), 3.92 (s, 6H); ^{13}C (C): 164.8 (x2), 153.1, 152.9, 144.3, 143.9, 142.7, 138.8, 138.7, 133.0, 128.63, 128.57, 128.2 (x2), 127.3, 127.0 (x2), 123.50, 122.6, 117.5, 79.1, 71.1, 56.0 (x2). Removal of the methoxycarbonyl groups by Procedure B gave **bis(diphenylmethyl) dicaffeoyl-L-tartrate (21)**, mp=135-136°C (dec.); ^{1}H NMR (M): 7.47 (d, 15.8, 2H), 6.91 (s, 2H),
20   6.79-7.36 (m, 20H), 6.10 (s, 2H), 6.07 (d, 15.8, 2H); ^{13}C (M): 167.4d, 166.8d, 150.2d, 148.8u, 146.9d, 140.7d (x2), 129.7u (x2), 129.2u (x2), 128.2u, 128.0u, 127.5d, 123.6u, 116.6u, 115.4u, 113.3u, 80.3u, 72.5u. Removal of the diphenylmethyl groups by Procedure D gave **L-DCTA (1)**, whose ^{1}H and ^{13}C NMR agreed with the literature.

Dicaffeoyl-D-tartaric acid (D-chicoric acid, D-DCTA) (2). D-Tartaric acid
25   was converted by Procedure C to **bis(diphenylmethyl) D-tartrate (2a)** as a white powder, mp=108-110°C; ^{1}H NMR (C): 7.28-7.34 (m, 20H), 6.99 (s, 2H), 4.76 (s, 2H); ^{13}C (C): 170.7, 139.0, 138.9, 128.6, 128.5, 128.4, 128.1, 127.6, 126.9, 79.2, 72.3; DIP/MS: 315 (2), 183 (37), 167 (100), 165 (47). Reaction of **2a** with **35a** via

Procedure F gave **bis(diphenylmethyl) bis[di(methoxycarbonyl)caffeoyl]-D-tartrate (2b)** mp=61-63°C; ^{1}H NMR (C): 7.50 (d, 16.0, 2H), 7.09-7.37 (m, 20H), 6.94 (s, 2H), 6.16 (d, 16.0, 2H), 6.04 (s, 2H), 3.93 (s, 6H), 3.92 (s, 6H); ^{13}C (C): 164.8 (x2), 153.1, 152.9, 144.3, 143.9, 142.7, 138.8, 138.7, 133.0, 128.63, 128.57, 128.2 (x2), 127.3, 127.0 (x2), 123.50, 122.6, 117.5, 79.1, 71.1, 56.0 (x2). Removal of the methoxycarbonyl groups by Procedure B gave **bis(diphenylmethyl) dicaffeoyl-D-tartrate (2c)**, mp=134-136°C (dec.); ^{1}H NMR (M): 7.49 (d, 15.8, 2H), 6.90 (s, 2H), 6.80-7.33 (m, 20H), 6.08 (s, 2H), 6.07 (d, 15.8, 2H); ^{13}C (M): 167.4d, 166.8d, 150.0d, 148.7u, 146.8d, 140.6d, 140.5d, 129.6u (x2), 129.1u (x2), 128.1u, 127.9u, 127.4d, 123.6u, 116.5u, 115.3u, 113.2u, 80.4u, 72.5u. Removal of the diphenylmethyl groups by Procedure D gave **D-DCTA (2)**, whose ^{1}H and ^{13}C NMR agreed with the literature.

Dicaffeoyl-meso-tartaric acid (meso-chicoric acid, meso-DCTA) (3). meso-Tartaric acid was converted by Procedure C to **bis(diphenylmethyl) meso-tartrate (3a)** as a white powder, mp=108-109°C; ^{1}H NMR (C): 7.18-7.27 (m, 20H), 6.82 (s, 2H), 4.72 (s,2H); ^{13}C (C): 170.2, 139.0, 138.7, 128.52, 128.45, 128.23, 128.18, 128.0, 127.2, 79.4, 73.1; DIP/MS: 315 (2), 183 (37), 167 (100), 165 (47); DIP/MS: 315 (2), 183 (35), 167 (100), 165 (48). Reaction of **3a** with **35a** via Procedure F gave **bis(diphenylmethyl) bis[di(methoxycarbonyl)caffeoyl]-meso-tartrate (3b)** mp=72-74°C; ^{1}H NMR (C): 7.59 (d, 16.0, 2H), 7.21-7.38 (m, 20H), 6.88 (s, 2H), 6.29 (d, 16.0, 2H), 6.02 (s, 2H), 3.91 (s, 6H), 3.90 (s, 6H); ^{13}C (C): 164.9, 164.8, 153.0, 152.9, 144.6, 143.9, 142.7, 139.01, 138.98, 133.01, 128.6, 128.5, 128.27, 128.1, 127.3, 127.1(x2), 123.5, 122.6, 117.8, 79.6, 71.6, 55.9 (x2). Removal of the methoxycarbonyl groups by Procedure B gave **bis(diphenylmethyl) dicaffeoyl-meso-tartrate (3c)**, mp=142-4°C (dec.); ^{1}H NMR (M): 7.55 (d, 16.0, 2H), 6.82 (s, 2H), 6.77-7.25 (m, 20H), 6.20 (d, 16.0, 2H), 6.01 (s, 2H); ^{13}C (M): 167.4d, 166.8d, 150.1d, 148.9u, 146.8d, 140.8 (x2)d, 129.6u, 129.5u, 129.2u, 129.1u, 128.2u, 128.1u, 127.3d, 123.5u, 116.5u, 115.4u, 113.4u, 80.8u, 72.8u. Removal of the diphenylmethyl groups by Procedure D gave **meso-DCTA (3)** whose ^{1}H and ^{13}C NMR agreed with the literature except that C-1 and C-2 of the tartaric acid portion were 3.5 upfield from that of an alleged meso-

chicoric acid from *Equisetum arvense*. Since the latter was isolated by chromatography with 1% NH_3 in MeOH, it may have been the ammonium salt. Dissociation of a carboxyl group deshields both the carbonyl and α-carbon resonances by 3-4ppm. This hypothesis was confirmed since the ^{13}C-NMR of the ammonium salt of 3 matched that

5 of the "meso chicoric acid" isolated from <u>Equisetum</u> which therefore was of the corresponding ammonium salt.

Dicaffeoyl-L-glyceric acid (19). Calcium L-glycerate dihydrate (Aldrich 37241-2) was dried to constant weight and reacted with **35a** by Procedure E to give **bis[di(methoxycarbonyl)caffeoyl]glyceric acid (19a)**, gum; ^{1}H NMR (C): 7.73 (d,

10 16.0, 1H), 7.66 (d, 16.0, 1H), 7.3-7.5 (m, 6H), 6.51 (d, 16.0, 1H), 6.44 (d, 16.0, 1H), 5.56 (m, 1H), 4.6-4.8 (m, 2H), 3.92 (s, 12H); ^{13}CNMR (C): 171.9, 165.9, 165.4, 153.1, 153.0, 152.9 (x2), 144.6 (x2), 143.83 (x2), 143.79, 142.7, 133.2, 133.1, 126.90, 126.85, 123.5 (x2), 122.6, 122.5, 118.5, 117.9, 70.2, 62.9, 56.0 (x4). Hydrolysis of **19a** by Procedure B but with a reaction time of only 10 min. gave **19**, mp 234-236°C;

15 Anal. ($C_{21}H_{18}O_{10}$) C, H; ^{1}H NMR (D): 7.54 (d, 15.9, 1H), 7.51 (d, 15.9, 1H), 7.0-7.1 (m, 4H), 6.78 (dd, 1.6, 8.1, 2H), 6.37 (d, 15.9, 1H), 6.29 (d, 15.9, 1H), 5.36 (m, 1H), 4.56 (m, 2H); ^{13}C (D): 168.5, 166.0, 165.6, 148.6, 148.5, 146.4, 146.0 (x2), 145.5, 125.2 (x2), 121.5, 121.4, 115.7 (x2), 115.0, 114.9, 113.0, 112.8, 70.2, 62.4.

Bis(3,4-dihydroxydihydrocinnamoyl)-L-tartaric acid (22). 3,4-

20 Dihydroxydihydrocinnamic acid was reacted by Procedure A to give a mixture of **3,4-dimethoxycarbonyldihydrocinnamic acid (22a)** and its anhydride which were separated by silica gel column chromatography and the latter hydrolyzed by 80% HOAC solution on a steam bath to give **(22a)**: gum, ^{1}H NMR (C): 7.16 (d, 7.2, 1H), 7.14 (s, 1H), 7.10 (d, 7.2, 1H), 3.90 (s, 6H), 2.97 (t, 8.0, 2H), 2.69 (t, 8.1, 2H); ^{13}C

25 NMR (C): 177.5, 153.4 (x2), 142.2, 140.8, 139.4, 126.7, 123.0, 122.9, 55.8 (x2), 35.0, 29.9. Reaction of **22a** by Procedure I gave the acid chloride which was subjected to Procedure G to give **bis(3,4-dimethoxycarbonyldihydrocinnamoyl)-L-tartaric acid (22b)**: gum, ^{1}H NMR (C): 7.18 (d, 8.1, 2H), 7.10 (dd, 8.1, 1.9, 2H), 7.09 (d, 1.9, 2H), 5.55 (s, 2H), 3.92 (s, 6H), 3.91 (s, 6H), 2.98 (m, 4H), 2.81 (m, 4H); ^{13} NMR (C):

171.0, 167.1, 154.7, 153.7, 142.0, 140.5, 139.3, 127.0, 123.2, 123.0, 70.3, 56.1, 56.0, 34.6, 30.1. Deprotection of **22b** by Procedure B and preparative HPLC gave **22**, as a gum which on analytical HPLC gave a single peak with a retention time of 2.5' (70% MeOH-H_2O+1% HOAc) or 3.1' (45% MeCN-H_2O +1% HOAc); ^{1}H NMR (D): 6.66 (bs, 2H), 6.54 (d, 8.0, 2H), 6.35 (bd, 7.5, 2H), 5.38 (s, 2H), 2.75 (m, 4H), 2.49 (m, 4H); ^{13}C NMR (D): 172.2, 170.8, 145.5, 143.5, 131.4, 118.5, 115.6, 115.5, 74.8, 35.3, 29.5; HRFABMS: Calcd. m/z for $C_{22}H_{22}O_{12}Na$, 501.1009; Fd. 501.1006.

Digalloyl-L-tartaric acid (25). Gallic acid (3,4,5-trihydroxybenzoic acid) was reacted by Procedure A to give **3,4,5-trimethoxycarbonylbenzoic acid (25a)** m.p.=143-144°C; ^{1}HNMR (C): 7.99 (s, 2H), 3.94 (s, 6H), 3.93 (s, 3H); ^{13}CNMR (C): 169.1, 152.6, 151.6, 143.8, 139.1, 127.8, 122.6, 56.4, 56.2. Procedure I converted **25a** to the acid chloride which reacted with bis(diphenylmethyl) L-tartrate (**1a**) according to Procedure F to give **bis(diphenylmethyl) bis(3,4,5-trimethoxycarbonylbenzoyl) L-tartrate (25b)**, gum: ^{1}H NMR (C): 7.62 (s, 4H), 7.30-7.36 (m, 20H), 6.96 (s, 2H), 6.08 (s, 2H), 3.94 (s, 6H), 3.92 (s, 12H); ^{13}CNMR (C): 164.0, 162.5, 152.4, 151.5, 143.6, 138.4, 138.1, 128.6, 128.54, 128.50, 128.3, 128.2, 127.5, 126.8, 126.5, 122.3, 79.3, 71.6, 56.4, 56.1. Sequential deprotection of **25b** by Procedures D and B and preparative HPLC gave **25**, as a gum which on analytical HPLC gave a single dominant peak with a retention time of 1.7'(10% MeOH-water+1% HOAc) or 4.8', (10% MeCN-H_2O +1% HOAc); ^{1}H NMR (D): 7.01 (s, 4H), 5.70 (s, 2H); ^{13}C NMR (D): 167.3, 164.8, 117.8, 108.8, 145.5, 139.1, 70.9; HRFABMS: Calcd. m/z for $C_{18}H_{14}O_{14}Na$, 477.0281; Fd. 477.0276.

Bis(3,4-dihydroxybenzoyl)-L-tartaric acid (26). 3,4-Dihydroxybenzoic acid (Aldrich 10,980-0) was reacted by Procedure A to give **3,4-dimethoxycarbonyl-benzoic acid (26a)** as an off-white solid, m.p.=168-169°C; ^{1}H NMR (C+M): 8.00 (dd, 8.6, 2.2, 1H), 7.99 (s, 1H), 7.39 (d, 8.6, 1H), 3.93 (s, 6H); ^{13}C NMR (C+M): 167.0, 153.3, 153.0, 146.1, 142.3, 129.7, 128.8, 125.0, 123.1, 56.1 (x2). Procedure I converted **26a** to the acid chloride which reacted by Procedure G to give **bis(3,4-dimethoxycarbonylbenzoyl)-L-tartaric acid (26b)**, gum; ^{1}H NMR (C+M): 8.04 (dd,

8.4, 1.9, 2H), 8.07 (bs, 2H), 7.46 (d, 8.4, 2H), 6.00 (s, 2H), 5.78 (bs, 2H), 3.93 (s, 3H),

3.92 (s, 3H); ^{13}CNMR (C+M): 167.5, 163.5, 152.7, 152.4, 146.3, 142.0, 128.5, 127.4,

124.6, 123.0, 71.8, 55.6 (x2). Deprotection of **26b** by Procedure B and preparative

HPLC gave **26** as a white solid, mp=175-176°C, Anal. ($C_{18}H_{14}O_{12}$+1.5H_2O) C, H; ^{1}H

5   NMR (D): 9.97 (s, 2H), 9.56 (s, 2H), 7.41 (d, 2.5, 2H), 7.39 (d, 8.1, 2H), 6.87 (dd, 8.1,

2.5, 1H), 5.73 (d, 2.7, 2H); ^{13}C NMR (D): 167.4, 164.5, 151.1, 145.1, 122.3, 119.1,

116.4, 115.4, 71.0.

      Bis(3,4-dihydroxyphenylacetyl)-L-tartaric acid (28). 3,4-Dihydroxyphenyl-

acetic acid was reacted by Procedure A to give **3,4-dimethoxycarbonylphenylacetic**

10   **acid (28a)**; oil; ^{1}H NMR (C): 7.28-7.17 (m, 3H), 3.89 (s, 6H), 3.63 (s, 2H); ^{13}C NMR

(C): 175.7, 153.2 (x2), 142.1, 141.5, 132.5, 127.9, 124.0, 123.0, 55.8 (x2), 40.1.

Reaction of **28a** by Procedure H gave the acid chloride which was subjected to

Procedure G to give **bis(3,4-dimethoxycarbonylphenylacetyl)-L-tartaric acid**

(28b), gum; ^{1}H NMR (M): 7.35-7.20 (m, 3H), 5.72 (s, H-2), 3.85 (s, 6H), 3.80 (s, 2H);

15   ^{13}C NMR (M): 171.3, 168.9, 154.74, 154.69, 143.6, 143.0, 134.2, 129.1, 125.3, 124.1,

72.7, 56.4 (x2), 40.3. Deprotection of **28b** by Procedure B and preparative HPLC gave

28 as a gum; Anal. ($C_{20}H_{18}O_{12}$+H_2O), calcd, C, 51.3, H, 4.3; found, C, 51.5, H, 4.8;

Analytical HPLC gave a single major peak with a retention time of 2.72' (10:1

MeCN:H_2O +1% HOAc) or 1.76' (5:1 MeOH:H_2O); ^{1}H NMR (M): 6.72-6.68 (m, 4H),

20   6.59 (dd, 8.0, 1.9, 2H), 5.65 (s, 2H), 3.59 (s, 4H); ^{13}C NMR (M): 172.6, 169.1, 146.2,

145.5, 126.2, 121.9, 117.6, 116.3, 72.4, 40.6.

Biochemical Characterization

      Following synthesis and chemical characterization, all compounds were

evaluated for capacity to inhibit IN activity in vitro, in the absence of cells, in the

25   disintegration assay. All IC_{50} values referred to and reported in Table 1 were

determined with this assay.

Disintegration Assay.

The disintegration activities of IN in the presence and absence of inhibitors was assayed *in vitro* as modified from the method of Chow (*Science* 255:723-726 (1992)). The following oligonucleotides (GenoSys, Inc) were used as DNA substrates:

T1 (16 mer):   5'-CAGCAACGCAAGCTTG-3';

5   T3 (30 mer):   5'-GTCGACCTGCAGCCCAAGCTTGCGTTGCTG-
3';

V2 (21mer):   5'-ACTGCTAGAGATTTTCCACAT-3';

V1/T2 (33 mer):   5'-
ATGTGGAAAATCTCTAGCAGGCTGCAGGTCGAC-3'.

10   The oligonucleotides were gel purified by the manufacturer. Oligonucleotide T1 was labeled at the 5'-end using T4 polynucleotide kinase and [γ-^{32}P] ATP (3000 Ci/mmol, Amersham). The substrate for assaying disintegration activity, the Y-oligomer, was prepared by annealing the labeled T1 strand with oligonucleotides T3, V2, and V1/T2. In a 20 μl volume, the DNA substrate (0.1 pmol) was incubated with

15   1.5 pmol recombinant IN for 60 minutes at 37°C in a buffer containing a final concentration of 20 mM HEPES pH 7.5, 10 mM DTT, 0.05% Nonidet P-40, and 10 mM MnCl$_2$. To each 19 μl of reaction mixture, 1 μl of inhibitor at various concentrations in solvent or solvent alone was added. The reaction was stopped by the addition of EDTA to a final 18 mM concentration. Reaction products were heated at

20   90°C for 3 minutes before analysis by electrophoresis on a 15% polyacrylamide gel with 7M urea in Tris-borate-EDTA buffer. All reactions were performed at enzyme excess and reactions were stopped within the linear range of the reaction. Although it has been suggested by one group that the inhibitory effects of bis-catechols are metal ion dependent, all reactions were performed in the presence of MnCl$_2$ rather than

25   MgCl$_2$. Our findings indicate that the DCTA's and DCQA's inhibit HIV IN whether Mg^{++} or Mn^{++} is the source of divalent cation and recent work from our groups suggests that metal ion is not required at all. These data are more consistent with the

inhibitory activity of bis-catechols against avian sarcoma virus IN. All compounds were first tested at 25 μM. For active compounds, IC_{50} analysis was determined from a median effect plot using CalcuSyn software (Biosoft, Cambridge, UK) on 0.5 $\log_{10}$ dilutions of inhibitor in triplicate experiments.

Selectivity Against IN of Compounds 1, 22, 25, 26 and 28

As shown in Table 2, compounds 1, 22, 25, 26 and 28 demonstrated selectivity against IN when tested against two different molecular clones of HIV. The derivation of these clones and the manner in which this comparison was made is as follows.

Generation of L-chicoric acid resistant strain $HIV_{NL4-3clone1-D4}$

HIV_{NL4-3} plasmid (a gift from Dr. P. Krogstad, UCLA, Los Angeles, CA), was transfected in HeLa cells using Lipofectin® (Gibco/BRL). Excess DNA was removed by washing and cells were co-cultured with H9 cells for 18 hours. The H9 cells were removed and re-cultured in growth medium. When the culture was 100% positive for HIV antigens by indirect immunofluorescence, the virus was inoculated onto H9 cells and incubated at 37°C for several weeks in the presence of 2 μM L-chicoric acid. When this culture was 100% positive the virus was isolated and one aliquot was passaged in a similar manner in 4 μM L-chicoric acid. Finally, virus was cultured in the presence of 8 μM L-chicoric acid and the resultant virus filter-clarified, aliquoted, and stored at -70°C.

HIV_{NL4-3}, following culture in 8 μM L-chicoric acid, was tested for resistance to the anti-HIV activity of the compound using a cytopathicity-based first described by Montefiori et al. This assay takes advantage of the lytic nature of T-cell tropic clones of HIV and decreased cell viability in this assay has been shown to correlate well with HIV replication. The fifty-percent effective dose (ED_{50}) of L-chicoric acid against HIV_{NL4-3} control virus was 400 nM while HIV_{NL4-3} passaged in the presence of 8 μM L-chicoric acid was completely resistant to the compound (Figure 14). Cloning and sequencing of virus from the HIV_{NL4-3} passaged in the presence of 8 μM L-

chicoric acid was undertaken to determine the molecular basis for resistance to L-chicoric acid and to isolate a resistant HIV clone.

The overall cloning and sequencing strategy is illustrated in Figure 15. For cloning and sequencing, HIV from 10 ml of culture was centrifuged at 33,000 x g for

5   4 hours at 4°C. Virions were lysed and RNA isolated using Purescript® (Gentra, Frederick, MD). Primers used to amplify cDNA under these conditions recognize the 5' and 3' ends of IN at nucleotide positions 3580-3605 ("INS" primer: 5'-ggtctccgcgggaatcaggaaagtac-3') and 4497-4522 ("INX" primer: 5'-gcttttctagaaatatacatatggtg-3') respectively, and generate a 943 base pair (bp) product.

10   First strand synthesis using INX primer and Superscript II®, an avian myeloblastosis virus RT (Gibco/BRL), was performed at 42°C for 50 minutes according to manufacturer's instructions. Thirty-eight cycle amplification was performed using *Pfu* thermostable DNA polymerase (Stratagene, La Jolla, CA) according to manufacturer's instructions. Optimum Mg^{++} concentration for these studies was determined to be

15   1mM. Conditions for polymerase chain reaction were: 96°C for one minute, 40°C for 30 seconds, 72°C for 2 minutes for the first two cycles followed by 96°C for one minute, 55°C for one minute and 72°C for 3 minutes for thirty-six cycles. The final cycle included a 10-minute, 70°C elongation step. The resulting reverse transcriptase polymerase chain reaction (RT-PCR) products were separated by agarose gel

20   electrophoresis and visualized by ethidium bromide staining. Appropriately sized products were eluted from the gel and blunt-end ligated into PCRScript® (Stratagene) for dideoxynucleotide sequencing using Sequenase II® (US Biochemical, Cleveland, OH) according to manufacturer's instructions. The entire integrase sequence was determined through the use of six oligonucleotide primers: INS, INX, Core 1, 5'-

25   cagctgtgataaatgtcagcta-3' (nt3721-3741), Core 2: 5'-ccatttgtactgctgtcttaa-3' (nt4122-4142), INSPF: 5'-gcaatttcaccagtactacagt-3' (nt3962-3983), and INSPR: 5'-gtagggaatgccaaattcctg-3' (nt4016-4036). Manual sequence analysis was confirmed by automated DNA sequencing.

Sequencing the integrase genes from both drug-resistant and control HIV$_{NL4-3}$ demonstrated several mutations. Control virus contained two silent mutations at nucleotides 3832 and 4009. These silent mutations are believed to arise from a discrepancy in the published sequences of HIV$_{NL4-3}$ and were likely not a result of

5   passage of HIV in the absence of inhibitor. Drug-resistant HIV$_{NL4-3}$ had the same silent mutations as well as a single G to A transition at nucleotide position 4025 leading to an amino acid change from glycine to serine at amino acid 140.

To determine whether this amino acid change was responsible for the observed resistant phenotype, the integrase genes from drug-resistant HIV$_{NL4-3}$ were cloned into

10   the native HIV$_{NL4-3}$ plasmid (pNL4-3). This cloning was accomplished through site-directed mutagenesis introducing several silent mutations immediately upstream and downstream of the integrase gene. These mutations generated two unique restriction sites: an upstream *SacII* and a downstream *XbaI* (Fig. 15). Introduction of these mutations allowed the entire integrase gene with only minimal upstream and

15   downstream nucleotides to be digested and "swapped" between drug-resistant and drug-sensitive clones. Two clones, 7-1 and 7-3, containing control integrase genes, wildtype except for silent mutations generating the restriction sites, and Clone 1-D4, containing drug-selected integrase with the G140S mutation were chosen for further study. Once transfected into HeLa cells and amplified in H9 cells, the viruses from all

20   three clones maintained the same sensitivity to zidovudine, a reverse transcriptase inhibitor, as the parental HIV$_{NL4-3}$ (Fig. 16a). The three clones containing wild-type integrase (the control viruses, clones 7-1 and 7-3 and wild-type HIV$_{NL4-3}$) maintained the L-chicoric acid-sensitive phenotype. Clone 1-D4, on the other hand, was resistant to the anti-HIV effects of L-chicoric acid (Figure 16b). The ED$_{50}$ for the drug-resistant

25   clone was >600-fold higher than the drug-sensitive clones.

Amino acid 140 of integrase has not been mutated previously using site-directed mutagenesis. Furthermore, a search of the GenBank database does not indicate any naturally occurring mutations at this site. This amino acid is also highly conserved in integrases from other retroviruses, retrotransposons, and transposable

elements of bacteria. Mutation at this site, from the highly conserved glycine to serine, has little effect on HIV replication but completely abrogates the anti-HIV activity of L-chicoric acid.

Assays, as described above, to determine the ED_{50} for a given compound

5   against the molecular clone $HIV_{NL4-3clone1-D4}$ and the parental clone HIV_{NL4-3} give an indication of the selectivity of the compound for inhibition of HIV replication through IN. Resistance to a compound, as measured by an increased ED_{50}, by clone $HIV_{NL4-3clone1-D4}$, implies selectivity of the compound for IN. Thus clone $HIV_{NL4-3clone1-D4}$ can be used to screen candidate IN inhibitors for selectivity.

10   **Assessing Capacity of L-CCA to act Synergistically**

Dual Antiviral Agent Measurements

Molecular clones of HIV included wild-type HIV_{NL4-3}, $HIV_{NL4-3\ M184V}$, and $HIV_{NL4-3\ JF26/A7}$. All three clones were a generous gift from P. Krogstad (UCLA, Los Angeles, CA). Viruses were initially transfected in adherent HeLa cells using

15   Lipofectin®. After 48 hours, H9 cells were added. Following 24 hours of co-culture, non-adherent cells were removed and cultured. Cells were monitored by indirect immunofluorescence and RT release as described below until the culture was 100% infected by HIV-1. Supernatant fluids were collected and clarified of cells by low-speed centrifugation followed by filtration through 0.45 μm filters.

20   **RT assay and immunofluorescence analysis.**

Each culture supernatant was precipitated with 0.42 ml of 30% polyethylene glycol as described previously by Robinson et al. (*J. Acquired Immune Defic. Syndr.* 2: 33-42 (1989)). Precipitated virus was lysed and incorporation of [³H]-thymidine into poly rA-oligo dT templates was measured according to a modification by

25   Robinson (ibid.) of the method first described by Poiesz *et al* (*Proc. Natl. Acad. Sci. USA.* 77: 7415-7419 (1980)). Trichloroacetic acid precipitable raw cpm were

determined on a Beckman β-scintillation counter. The mean cpm for the triplicate
infections was determined and mean background cpm from three cell control cultures
run in parallel to each assay were subtracted. The resultant corrected cpm were
multiplied by 8 to convert to cpm/ml of culture supernatant fluid. For

5   immunofluorescence analysis, cells from triplicate wells were combined and spotted
onto glass slides. The percentage of cells expressing HIV antigens was quantitated
using pooled human anti-HIV serum followed by fluorescein-conjugated goat anti-
human IgG and observation under fluorescence microscopy as described by Robinson
(ibid.).

10   **Synergy Analysis**

Compounds:

Zidovudine, DDC, and 2',3'-dideoxyinosine (DDI) were purchased from
Sigma Chemical Co (St. Louis, MO). All three were reconstituted to 1 mM stock
solutions in deionized water and stored at –20°C until use. Michael Melnick (Agouron

15   Pharmaceuticals, San Diego) provided Nelfinavir. Manfred Reinecke (Texas Christian
University, Fort Fort Worth, TX) provided L-chicoric acid. Both were reconstituted in
deionized water and stored at –70°C until use. All stocks were diluted in growth
medium and filter-clarified before being tested for cell toxicity and anti-HIV activity.

Anti-HIV Assays:

20   Anti-HIV activity of compounds was determined both alone and in
combination using a cytopathicity based assay as described above. This assay utilizes
Finter's neutral red dye; protection from HIV-induced cell death is highly correlated
with HIV-1 antigen synthesis, RT release, and the formation of infectious progeny
virions. All drugs were tested at concentrations well below their toxic doses either

25   alone or in combination. The fifty-percent effective dose (ED_{50}) was calculated for
triplicate infections. Mean ED_{50} (shown in Figure 5) were calculated for each drug

against each HIV variant from a minimum of three experiments performed in triplicate.

Mixed Dose Effect Analyses:

Mixed dose effect analyses were performed using the method of Chou and
5   Talalay (*Adv. Enzyme Regul.* 22: 27-55 (1984)) and commercially available software:
CalcuSyn for Windows (Biosoft, Ferguson, MO, USA). Experiments were designed at
a fixed ratio of drugs; the ratio for each drug combination was determined based on
the ED_{50} of each drug alone against each HIV variant. Combination indices were
calculated on representative experiments performed in triplicate according to the
10   following formula of Chou and Talalay:

$$fa/fu = (D/D_m)^m$$

Where fa is the fraction affected by the dose, fu is the unaffected fraction, D is
the dose of the drug, D_m is the median-effect dose determined to be the x-intercept of
15   the median-effect plot, and m is the sigmoidicity of the dose-effect curve, determined
by the slope of the median-effect plot. The median effect plot is based on the
following equation:

$$\log (fa/fu) = m \log (D) - m \log (D_m)$$

20

This equation yields a straight-line y= mx+b; therefore, the x intercept is the
$\log (D_m)$ value and the slope is m.

The combination index (CI) is based on the multiple drug-effect equation of
Chou and Talalay where a CI=1 is additive, greater than 1 is antagonism and less than

1 is synergism. This equation, first defined by Chou and Talalay (*Trends Pharmacol. Sci.* 4: 450-454 (1983)) is:

$$CI = \frac{(D)_1}{(D_x)_1} + \frac{(D)_2}{(D_x)_2}$$

5

Where D_1 is the dose of drug 1 and D_2 is the dose of drug 2 **in combination** that results in x% inhibition and $(D_x)_1$ and $(D_x)_2$ are the doses of drug 1 and drug 2 **alone** that result in x% inhibition. The results of mixed drug analyses for the pairwise

10   combinations of L-CCA plus DDC, L-CCA plus nelfinavir, and L-CCA plus zidovudine are shown in Tables 4-6 respectively.

Triple Antiviral Agent Measurements:

Anti-HIV Compounds:

ZDV was purchased from Sigma Chemical Company (St. Louis, MO) and was

15   reconstituted with cold deionized water to a final concentration of 1 mM. Protease inhibitor (PI) (AG1350) (Agouron Pharmaceuticals, La Jolla, CA) and reconstituted in 14% ethanol/37.5% DMSO/48.5% H_2O to a final concentration of 7 mM. AG1350 is slightly (less than 10-fold) less active than the recently FDA-approved PI, Viracept®. The L-CCA was dissolved in H_2O to a final concentration of 2.1 mM.

20   **Cells and Virus.**

The two clinical isolates were obtained from patients visiting the UCI Medical Center AIDS Clinic under an IRB-approved protocol. HIV_{R19} and HIV_{R45} were obtained approximately three weeks after inoculation with 100 µl of freshly drawn serum onto MT-2 cells (the time required for the MT-2 cells to become infected).

Previous work has indicated that such isolates of HIV are predominantly syncytium-inducing, rapid-growing, T-cell-tropic isolates of HIV. Cell-free supernatants of HIV_{R19} and HIV_{R45} from MT-2 cells were inoculated onto phytohemagglutinin-stimulated PMBCs, cultured in growth medium supplemented with 11.5% FBS and

5   20 units of recombinant human IL-2/ml (Boehringer-Mannheim, Indianapolis, IN), and HIV was isolated at peak RT production (7 and 10 days). Both isolates were highly cytopathic and grew to similar titers with similar replication kinetics in tissue culture. The resulting limited passage, cell-free supernatant was directly inoculated onto MT-2 cells for use in antiviral assays.

10   **Cell Toxicity and Anti-HIV Assays:**

Cell toxicity and anti-HIV assays were performed as reported above. Briefly, compounds were diluted 1:1 in growth medium, filter sterilized, and further two-fold serially diluted from 1:8 to 1:1280 in triplicate wells of a microtiter plate. To each 50 μl of diluted drug, 50 μl of growth medium was added followed by 100 μl of MT-2

15   cell suspension (2×10^5 cells). Cells were incubated with drug for 48 hours at 37°C, then harvested for cell viability in a neutral red dye assay as described. Similar toxicities were also seen if the cells were incubated for 72 hours prior to harvest.

Anti-HIV assays were performed as described above. Based upon cell toxicity data, compounds were diluted in growth medium such that a final 1:4 dilution of the

20   sample would result in a concentration of sample that inhibited MT-2 cell growth by 5% (5% lethal dose, LD_5). The compounds were then two-fold serially diluted in triplicate. To each 50 μl of diluted compound, 50 μl of HIV_{LAI} was added and the virus-drug mixture was incubated for 1 hr at 37°C. Next, 100 μl of MT-2 cell suspension (2×10^5 cells) was added to each well and cells were incubated for 72 hr

25   at 37°C. Final multiplicity of infection (MOI) was 1-5. Cells were harvested to quantitate cytopathic effect using a neutral red dye assay as described. The antiviral concentration reported is the concentration of drug necessary to protect MT-2 cells

from fifty percent viral-induced cell death; this is referred to as the fifty percent effective dose (ED_{50}).

The results reported herein clearly demonstrate that the addition of a first generation IN inhibitor to regimens using either a PI or ZDV improves upon the *in vitro* anti-HIV effect of that regimen. For all of the triple combination studies (Figs. 6-9), all three inhibitors were used at suboptimal concentrations (below the ED_{50}). In addition, if L-CCA is added to ZDV and a PI, one can effectively reduce by at least 33% the amount of ZDV and PI required to provide an equivalent anti-HIV effect. *In vitro* combination analyses may or may not predict how combinations of antiviral agents will behave *in vivo*. For HIV, combinations of protease inhibitors and reverse transcriptase inhibitors demonstrated additive to synergistic effects *in vitro*, which were similar to their *in vivo* effects. With one major limiting factor in anti-HIV combination therapy being the cost of the antiviral agents, especially PIs, such a reduction could substantially increase the number of patients who could be on combination therapy regimens. The results of these *in vitro* studies, if they were to translate into *in vivo* results, could have a substantial impact on both the efficacy and costs of newer anti-HIV therapies.

The addition of L-chicoric acid to either zidovudine or protease inhibitor improved upon the observed anti-HIV activity of either compound alone. When all three drugs were combined, the anti-HIV activity was substantially better than either of the three compounds alone or any combination of two inhibitors. Doses of both zidovudine and protease inhibitor could be reduced by more than 33% for an equivalent anti-HIV effect if L-chicoric acid was added. The improved anti-HIV activity was observed with a tissue culture adapted strain of HIV (HIV_{LAI}) and with limited passage clinical isolates of HIV (HIV_{R19} and HIV_{R45}). These data demonstrate that a first generation HIV integrase inhibitor is at least additive and probably synergistic in combination with existing multi-drug regimens. The modified integrase inhibitors disclosed herein show similar synergistic properties. It is expected that the variations in molecular structure will prove advantageous in actual patient trials. For

example, replacing ester linkages with more stable amide or even aliphatic linkages significantly improves the effectiveness of modified integrase inhibitors. A version of compound 36 in which the amide bonds are replaced with ester bonds is virtually ineffective

5   Many alterations and modifications may be made by those having ordinary skill in the art without departing from the spirit and scope of the invention. Therefore, it must be understood that the illustrated embodiment has been set forth only for the purposes of example and that it should not be taken as limiting the invention which is properly defined by the following claims.

10   The words used in this specification to describe the invention and its various embodiments are to be understood not only in the sense of their commonly defined meanings, but to include by special definition in this specification structure, material or acts beyond the scope of the commonly defined meanings. Thus if an element can be understood in the context of this specification as including more than one meaning, 15   then its use in a claim must be understood as being generic to all possible meanings supported by the specification and by the word itself.

We claim:

1.   A method for treating HIV infections comprising administering a mixture of a reverse transcriptase inhibitor, and/or a protease inhibitor and an integrase inhibitor.

5   2.   The method of Claim 1 further comprising administering more than one reverse transcriptase inhibitor and/or more than one protease inhibitor.

3.   The method of Claim 1 further comprising administering more than one integrase inhibitor.

10   4.   The method of Claim 2 further comprising administering more than one integrase inhibitor.

5.   The method of Claim 1, wherein the integrase inhibitor is selected from a group consisting of chicoric acid 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-lysine

6.   The method of Claim 1, wherein the reverse transcriptase inhibitor is selected from a group consisting of 2',3'-dideoxycytidine, 2',3'-dideoxyinosine and zidovudine.

7.   The method of Claim 1, wherein the protease inhibitor is Nelfinavir.

8.   A composition for treating HIV infections comprising a mixture of a reverse transcriptase inhibitor, and/or a protease inhibitor and an integrase inhibitor.

9.   The composition of Claim 8, wherein the integrase inhibitor is selected from a group consisting of chicoric acid 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric

5   acid, 2,3-di-(3,4,5-trihydroxybenzoyl-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-lysine

10   10.   The composition of Claim 8, wherein the reverse transcriptase inhibitor is selected from a group consisting of 2',3'-dideoxycytidine, 2',3'-dideoxyinosine and zidovudine.

11.   The composition of Claim 8, wherein the protease inhibitor is Nelfinavir.

15   12.   The composition of Claim 8 further comprising more than one reverse transcriptase inhibitor and/or more than one protease inhibitor.

13.   The composition of Claim 8 further comprising more than one integrase inhibitor.

14.   The composition of Claim 12 further comprising more than one integrase inhibitor.

15.   An integrase inhibitor selected from a group consisting of 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-lysine

16.   An integrase inhibitor having the formula:

$$
\begin{array}{c}
R \\
| \\
R_2 — C — R_1 \\
| \\
(CH_2)n \\
| \\
R_4 — C — R_3 \\
| \\
R_5,
\end{array}
$$

wherein n is between 0 and 4;

wherein R_1 and R_3 are selected from the group consisting of hydrogen, OR_6, NR_6 and aralkyl groups;

wherein R_7 is selected from the group consisting or hydrogen, alkyl and aralkyl;

wherein R and R_5 are selected from the group consisting of hydrogen, $COOR_7$ and $CONHR_7$;

wherein R_6 is

$$\overset{O}{\underset{\|}{-C}}-X-\left\langle\underset{Y}{\overset{(R_8)m}{\bigcirc}}\right\rangle,$$

wherein X is a hydrocarbyl group with from 0 to 10 carbon atoms, Y is selected from CH=CH, n=CH, CH=N, O, S, or NR_7. m is between 0 and 3, and R_8 is selected from the group consisting of hydrogen, hydroxy, halo, lower alkoxy, alkycarbonyloxy and alkoxycarbonyloxy or a cyclic carbonate group with hydroxy groups on adjacent carbons; and wherein R_2 and R_4 are hydrogen.

17.   The integrase inhibitor of Claim 16, wherein R_2 and R_4 combine with each other to form a cycloalkyl ring.

18.   The integrase inhibitor of Claim 16, wherein R_2 and R_4 are combined with R_1 and R_4, respectively, to form aromatic rings.

19.   The integrase inhibitor of Claim 18, wherein the aromatic rings are substituted with from one to three substituents selected from OR_6 and NR_6 groups.

20.   The integrase inhibitor of Claim 16, wherein when R and R_5 are $COOR_7$ or $CONHR_7$, and R_1, R_2 and R_3, R_4 combine to form an arylidene group.

21.   The integrase inhibitor of Claim 20, wherein the arylidene group is substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, halo, alkoxy, alkycarbonyloxy and alkoxycarbonyloxy.

22.   An integrase inhibitor having the formula:

$$R\text{-}(C)_n\text{-}\overset{O}{\overset{\|}{C}}\text{-}L\text{-}\overset{O}{\overset{\|}{C}}\text{-}(C)_n\text{-}R,$$

wherein R is 1,4-dicaffeoyl, n is between 0 and 6 and L comprises an amino acid linked by an ester or amide bond.

23.   An integrase inhibitor having the formula:

$$R\text{-}(C)_n\text{-}C\text{-}L\text{-}C\text{-}(C)_n\text{-}R,$$

wherein R is 1,4-dicaffeoyl, n is between 0 and 6 and L

comprises a chain of between 1 and 6 carbon atoms.

Compounds 1, 2, 3
L-, D-, m- chicoric Acid

Fig. 1a

Compound 19
1,2-Dicaffeoyl-L-glyceric Acid

Fig. 1b

Compound 22
**Bis-(3,4-dihydroxydihydrocinnamoyl)-L-tartaric acid**

Fig. 1c

**Compound 25**
Digalloyl-L-tartaric acid

Fig. 2a

Compound 26
**Bis (3,4-dihydroxybenzoyl) L-tartaric acid**

Fig. 2b

Compound 28
Bis-(3,4-dihydroxyphenylacetyl)-L-tartaric acid

Fig. 2c

Compound 35
2,3-Dicaffeoyldiamidopropionic acid

Fig. 3a

Compound 36
bis-3,4-dicaffeoyldiamidobenzoic Acid

Fig. 3b

Compound 37
**Di-3,4-dihydroxybenzylidene succinic acid**

Fig. 3c

Compound 38
Di-3,4-dihydrodihydroxybenzylidine succinic acid

Fig. 4a

Compound 39
2,3-Dicaffeoyl-L-serine

Fig. 4b

Compound 40
bis-Dicaffeoyl-L-isoserine

Fig. 4c

Compound 41
**1,4-Dicaffeoyl-L-Lysine**

Fig. 4d

Fig. 5

Fig. 6

# Fig. 7

Fig. 8

Fig. 9

Fig. 10

Scheme 1

Fig. 11

Scheme 2

Fig. 12

$$n = 2, R = OH$$

[A]

$$22a: \quad n = 2, R = OM$$

[I]

[G]

$$22b: \quad n = 2, R = OM$$

[B]

$$22: \quad n = 2, R = OH$$

$$n = 0, R = OH$$

[A]

$$26a: \quad n = 0, R = OM$$

[I]

[G]

$$26b: \quad n = 0, R = OM$$

[B]

$$26: \quad n = 0, R = OH$$

$$n = 1, R = OH$$

[A]

$$28a: \quad n = 1, R = OM$$

[H]

[G]

$$28b: \quad n = 1, R = OM$$

[B]

$$28: \quad n = 1, R = OH$$

Scheme 3

Fig. 13

COOH

R=3,4,5[OH]₃

25a:R=3,4,5[OM]₃   25:X=H,R=3,4,5[OH]₃

25b:X=DPM,R=3,4,5[OM]₃

R=3,5[OH]₂

27a:R=3,5[OM]₂

27b:X=H,R=3,5[OM]₂   27:X=H,R=3,5[OH]₂

31c:R=2,3[OM]₂   →   31d:X=DPM,R=2,3[OM]₂

31e:X=H,R=2,3[OM]₂

31:X=H,R=2,3[OH]₂

32c:R=2,5[OM]₂   →   32d:X=DPM;R=2,5[OM]₂

32e:X=H,R=2,5[OM]₂

32:X=H,R=2,5[OH]₂

R=3,4-F₂   →   →   33:R=3,4-F₂,X=H

Scheme 4

Fig. 14

Fig. 15

Fig. 16a

Fig. 16b

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A01N 43/42, 43/04, 37/10

US CL : 514/308, 50, 571

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/308, 50, 571

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN: COMPOUNDS AND METHODS OF USE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,724,232 A (RIDEOUT ET AL) 09 FEBRUARY 1988, see entire patent	1-14
Y	US 5,705,647 A (BABU ET AL) 06 JANUARY 1998, see entire patent	1-14
Y - X	ROBINSON et al. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proceedings of the National Academy of Science. June 1996, Vol. 93, pages 6326-6331, see entire document.	1-23 ---- 16-21 and 23

☐ Further documents are listed in the continuation of Box C.   ☐ See patent family annex.

*	Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	
"E"	earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	
"O"	document referring to an oral disclosure, use, exhibition or other means	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"P"	document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
12 AUGUST 1999	**03 SEP 1999** -

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer RUSSELL TRAVERS
Facsimile No. (703) 305-3230	Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)*

We claim:

1.   A method for treating HIV infections comprising administering a mixture of a reverse transcriptase inhibitor, and/or a protease inhibitor and an integrase inhibitor.

5   2.   The method of Claim 1 further comprising administering more than one reverse transcriptase inhibitor and/or more than one protease inhibitor.

3.   The method of Claim 1 further comprising administering more than one integrase inhibitor.

10   4.   The method of Claim 2 further comprising administering more than one integrase inhibitor.

5.   The method of Claim 1, wherein the integrase inhibitor is selected from a group consisting of chicoric acid 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-

15   tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-

20   lysine

SUBSTITUTE SHEET

6.   The method of Claim 1, wherein the reverse transcriptase inhibitor is selected from a group consisting of 2',3'-dideoxycytidine, 2',3'-dideoxyinosine and zidovudine.

7.   The method of Claim 1, wherein the protease inhibitor is Nelfinavir.

8.   A composition for treating HIV infections comprising a mixture of a reverse transcriptase inhibitor, and/or a protease inhibitor and an integrase inhibitor.

9.   The composition of Claim 8, wherein the integrase inhibitor is selected from a group consisting of chicoric acid 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric   acid,   2,3-di-(3,4-dihydroxybenzoyl)-tartaric   acid,   2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid,   2,3-di-(3,4,5-trihydroxybenzoyl-tartaric   acid,   2,3-dicaffeoyldiamidopropionic   acid,   1,2,-dicaffeoyl-glyceric   acid,   bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidine   succinic   acid,   2,3-dicaffeoyl-serine,   bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-lysine

10.   The composition of Claim 8, wherein the reverse transcriptase inhibitor is selected from a group consisting of 2',3'-dideoxycytidine, 2',3'-dideoxyinosine and zidovudine.

SUBSTITUTE SHEET

11.   The composition of Claim 8, wherein the protease inhibitor is Nelfinavir.

12.   The composition of Claim 8 further comprising more than one reverse transcriptase inhibitor and/or more than one protease inhibitor.

5   13.   The composition of Claim 8 further comprising more than one integrase inhibitor.

14.   The composition of Claim 12 further comprising more than one integrase inhibitor.

15.   An integrase inhibitor selected from a group consisting of 10   2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric   acid,   2,3-di-(3,4-dihydroxybenzoyl)-tartaric   acid,   2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid,   2,3-di-(3,4,5-trihydroxybenzoyl-tartaric   acid,   2,3-dicaffeoyldiamidopropionic   acid,   1,2,-dicaffeoyl-glyceric   acid,   bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-15   3,4-dihydrodihydroxybenzylidine   succinic   acid,   2,3-dicaffeoyl-serine,   bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-lysine

SUBSTITUTE SHEET

16.   An integrase inhibitor having the formula:

$$R_2 - \overset{\overset{\displaystyle R}{\displaystyle |}}{\underset{\displaystyle |}{C}} - R_1$$
$$(CH_2)n$$
$$R_4 - \overset{\displaystyle |}{\underset{\displaystyle |}{C}} - R_3$$
$$R_5,$$

wherein n is between 0 and 4;

wherein R_2 and R_4 are hydrogen

wherein R_1 and R_3 are selected from the group consisting of hydrogen, OR_6, NR_6 and aralkyl groups;

wherein R_6 is

$$-\overset{\overset{\displaystyle O}{\displaystyle ||}}{C}-X-\langle\langle \quad \rangle\rangle^{(R_8)m}_{Y,}$$

wherein X is a hydrocarbyl group with from 0 to 10 carbon atoms, Y is selected from CH=CH, N=CH, CH=N, O, S, or NR_7. m is between 0 and 3, and R_8 is selected from the group consisting of hydrogen, hydroxy, halo, lower alkoxy, alkycarbonyloxy and alkoxycarbonyloxy or a cyclic carbonate group with hydroxy groups on adjacent carbons; and

wherein R and R_5 are selected from the group consisting of hydrogen, $COOR_7$ and $CONHR_7$;

SUBSTITUTE SHEET

wherein R_7 is selected from the group consisting or hydrogen, alkyl and aralkyl; and

wherein when R and R_5 are $COOR_7$ and R_7 is hydrogen and R_1 and R_3 are OR_6, then R_6 and R_8 are hydroxy, m is not 2 and X and Y are not CH=CH.

17. The integrase inhibitor of Claim 16, wherein R_2 and R_4 combine with each other to form a cycloalkyl ring.

18. The integrase inhibitor of Claim 16, wherein R_2 and R_4 are combined with R_1 and R_4, respectively, to form aromatic rings.

19. The integrase inhibitor of Claim 18, wherein the aromatic rings are substituted with from one to three substituents selected from OR_6 and NR_6 groups.

20. The integrase inhibitor of Claim 16, wherein when R and R_5 are $COOR_7$ or $CONHR_7$, and R_1, R_2 and R_3, R_4 combine to form an arylidene group.

21. The integrase inhibitor of Claim 20, wherein the arylidene group is substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, halo, alkoxy, alkycarbonyloxy and alkoxycarbonyloxy.

SUBSTITUTE SHEET

22.   An integrase inhibitor having the formula:

$$R\text{-}(C)_n\text{-}\overset{\overset{\displaystyle O}{\|}}{C}\text{-}L\text{-}\overset{\overset{\displaystyle O}{\|}}{C}\text{-}(C)_n\text{-}R,$$

wherein R is 1,4-dicaffeoyl, n is between 0 and 6 and L comprises

an amino acid linked by an ester or amide bond.

23.   An integrase inhibitor having the formula:

$$R\text{-}(C)_n\text{-}\overset{\overset{\displaystyle O}{\|}}{C}\text{-}L\text{-}\overset{\overset{\displaystyle O}{\|}}{C}\text{-}(C)_n\text{-}R,$$

wherein R is 1,4-dicaffeoyl, n is between 0 and 6 and L comprises

a chain of between 1 and 6 carbon atoms.

SUBSTITUTE SHEET

P●NT COOPERATION TREA●

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:
KIRCHANSKI, Stefan, J. Hogan & Hartson LLP Biltmore Tower, Suite 1900 500 South Grand Avenue Los Angeles, CA 90017 ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)
24 July 2000 (24.07.00)

Applicant's or agent's file reference
36316.00005

IMPORTANT NOTIFICATION

International application No.	International filing date (day/month/year)
PCT/US99/06700	26 March 1999 (26.03.99)

1. The following indications appeared on record concerning:

[ ] the applicant   [ ] the inventor   [X] the agent   [ ] the common representative

Name and Address	State of Nationality	State of Residence
KIRCHANSKI, Stefan, J. Graham & James LLP 14th floor 801 S. Figueroa Street Los Angeles, CA 90017-5554 United States of America	**Telephone No.** 213 624 2500	
	Facsimile No. 213 623 4581	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

[ ] the person   [ ] the name   [X] the address   [ ] the nationality   [ ] the residence

Name and Address	State of Nationality	State of Residence
KIRCHANSKI, Stefan, J. Hogan & Hartson LLP Biltmore Tower, Suite 1900 500 South Grand Avenue Los Angeles, CA 90017 United States of America	**Telephone No.** 213 337 6700	
	Facsimile No. 213 337 6701	
	Teleprinter No.	

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

[X] the receiving Office   [ ] the designated Offices concerned

[ ] the International Searching Authority   [X] the elected Offices concerned

[X] the International Preliminary Examining Authority   [ ] other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer G. Bähr
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

3 1 JUL 2000

To: STEFAN J. KIRCHANSKI
GRAHM & JAMES LLP
801 S. FIGUEROA STREET 14TH FLOOR
LOS ANGELES, CALIFORNIA 90017-5554

PCT

NOTIFICATION OF TRANSMITTAL OF
INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing (day/month/year)	**26 JUL 2000**

Applicant's or agent's file reference	IMPORTANT NOTIFICATION
36316.00005	

International application No.	International filing date (day/month/year)	Priority Date (day/month/year)
PCT/US99/06700	26 MARCH 1999	27 MARCH 1998

Applicant

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. **REMINDER**

   The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

   Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

   For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US	Authorized officer
Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	RUSSELL TRAVERS
Facsimile No. (703) 305-3230	Telephone No. (703) 308-1235

Form PCT/IPEA/416 (July 1992)*

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 36316.00005	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/06700	International filing date *(day/month/year)* 26 MARCH 1999	Priority date *(day/month/year)* 27 MARCH 1998

International Patent Classification (IPC) or national classification and IPC IPC(7): A01N 43/42, 43/04, 37/10 and US Cl.: 514/308, 50, 571

Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of _4_ sheets.

   ☑ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of _2_ sheets.

3. This report contains indications relating to the following items:

   I   ☒   Basis of the report

   II   ☐   Priority

   III   ☐   Non-establishment of report with regard to novelty, inventive step or industrial applicability

   IV   ☐   Lack of unity of invention

   V   ☒   Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

   VI   ☐   Certain documents cited

   VII   ☐   Certain defects in the international application

   VIII   ☐   Certain observations on the international application

Date of submission of the demand 25 OCTOBER 1999	Date of completion of this report 26 JUNE 2000

Name and mailing address of the IPEA/US
   Commissioner of Patents and Trademarks
   Box PCT
   Washington, D.C. 20231
Facsimile No.   (703) 305-3230
	Authorized officer
	
	RUSSELL TRAVERS
	
	Telephone No. (703) 308-1235

Form PCT/IPEA/409 (cover sheet) (July 1998)*

I. Basis of the report

1. With regard to the **elements** of the international application:*

☐ the international application as originally filed

☒ the description:

pages _____(See Attached)_____ , as originally filed

pages _____ , filed with the demand

pages _____ , filed with the letter of _____

☒ the claims:

pages _____(See Attached)_____ , as originally filed

pages _____ , as amended (together with any statement) under Article 19

pages _____ , filed with the demand

pages _____ , filed with the letter of _____

☒ the drawings:

pages _____(See Attached)_____ , as originally filed

pages _____ , filed with the demand

pages _____ , filed with the letter of _____

☒ the sequence listing part of the description:

pages _____(See Attached)_____ , as originally filed

pages _____ , filed with the demand

pages _____ , filed with the letter of _____

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

☐ the language of publication of the international application (under Rule 48.3(b)).

☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/ or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☐ contained in the international application in printed form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ The statement that the information recorded in computer readable form is identical to the writen sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

☒ the description, pages____NONE____

☒ the claims, Nos. ____NONE____

☒ the drawings, sheets/fig ____NONE____

5. ☒ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* *Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

**Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.*

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. statement

Novelty (N)	Claims	1-23	YES
	Claims	none	NO
Inventive Step (IS)	Claims	17-23	YES
	Claims	1-16	NO
Industrial Applicability (IA)	Claims	1-23	YES
	Claims	none	NO

2. citations and explanations (Rule 70.7)

Claims 1-23 meet the criteria set out in PCT Article 33(2), because the prior art does not teach or fairly suggest employing the claimed medicaments concomitantly.

Claims 1-16 lack an inventive step under PCT Article 33(3) as being obvious over Rideout et al, Babu et al and Robinson et al. Rideout et al, Babu et al and Robinson et al teach the claimed compounds as old and well known antiviral medicaments. Specifically, Robinson et al teach chicoric acid as active against the HIV etiological agent, motivating the skilled artisan to employ this medicament. Claims 1-16 read on employing chicoric acid against HIV. To employ old and well known antiviral medicaments concomitantly to treat the same viral condition lacks and inventive step.

Claims 1-23 meet the criteria set out in PCT Article 33(4) for industrial applicability.

-------------------- NEW CITATIONS --------------------

NONE

Supplemental Box
(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII   Sheet 10

I. BASIS OF REPORT:

This report has been drawn on the basis of the description,
page(s) 1-43, as originally filed.
page(s) NONE, filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the claims,
page(s) NONE, as originally filed.
page(s) NONE, as amended under Article 19.
page(s) NONE, filed with the demand.
and additional amendments:
Claim pages 44-49, filed with the letter of 05 June 2000.

This report has been drawn on the basis of the drawings,
page(s) 1-16 , as originally filed.
page(s) NONE, filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the sequence listing part of the description:
page(s) NONE, as originally filed.
pages(s) NONE, filed with the demand.
and additional amendments:
NONE

5. (Some) amendments are considered to go beyond the disclosure as filed:
NONE

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year)	Applicant's or agent's file reference
17 February 2000 (17.02.00)	

International application No.	Applicant's or agent's file reference
PCT/US99/06700	36316.00005

International filing date (day/month/year)	Priority date (day/month/year)
26 March 1999 (26.03.99)	27 March 1998 (27.03.98)

Applicant

ROBINSON, W., Edward, Jr. et al

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

25 October 1999 (25.10.99)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Claudio Borton
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

Form PCT/IB/331 (July 1992)

09/647270

PATENT COOPERATION TREATY

PCT

NOTIFICATION CONCERNING SUBMISSION OR TRANSMITTAL OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

KIRCHANSKI, Stefan, J.
Hogan & Hartson LLP
Biltmore Tower, Suite 1900
500 South Grand Avenue
Los Angeles, CA 90017
ETATS-UNIS D'AMERIQUE

RECEIVED TECH CENTER 1600 JAN 1 4 2002

Date of mailing (day/month/year) 13 October 2001 (13.10.01)	
Applicant's or agent's file reference 36316.00005	**IMPORTANT NOTIFICATION**
International application No. PCT/US99/06700	International filing date (day/month/year) 26 March 1999 (26.03.99)
International publication date (day/month/year) 30 September 1999 (30.09.99)	Priority date (day/month/year) 27 March 1998 (27.03.98)
Applicant **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA et al**	

1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).

2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.

3. An **asterisk(*)** appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

4. The **letters "NR"** appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date	Priority application No.	Country or regional Office or PCT receiving Office	Date of receipt of priority document
27 Marc 1998 (27.03.98)	60/079,764	US	07 May 1999 (07.05.99)
17 July 1998 (17.07.98)	60/093,208	US	27 Sept 2001 (27.09.01)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Taieb AKREMI
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

Form PCT/IB/304 (July 1998)   004369834

PATENT COOPERATION TREATY

PCT

INFORMATION CONCERNING ELECTED OFFICES NOTIFIED OF THEIR ELECTION

(PCT Rule 61.3)

From the INTERNATIONAL BUREAU

To:

KIRCHANSKI, Stefan, J.
Graham & James LLP
14th floor
801 S. Figueroa Street
Los Angeles, CA 90017-5554
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year)	
17 February 2000 (17.02.00)	HAR 0 2

Applicant's or agent's file reference	
36316.00005	**IMPORTANT INFORMATION**

International application No.	International filing date (day/month/year)	Priority date (day/month/year)
PCT/US99/06700	26 March 1999 (26.03.99)	27 March 1998 (27.03.98)

Applicant	
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA et al	

1. The applicant is hereby informed that the International Bureau has, according to Article 31(7), notified each of the following Offices of its election:

   AP :GH,GM,KE,LS,MW,SD,SL,SZ,UG,ZW
   EP :AT,BE,CH,CY,DE,DK,ES,FI,FR,GB,GR,IE,IT,LU,MC,NL,PT,SE
   National :AU,BG,BR,CA,CN,CZ,DE,IL,JP,KP,KR,MN,NO,NZ,PL,RO,RU,SE,SK,US

2. The following Offices have waived the requirement for the notification of their election; the notification will be sent to them by the International Bureau only upon their request:

   EA :AM,AZ,BY,KG,KZ,MD,RU,TJ,TM
   OA :BF,BJ,CF,CG,CI,CM,GA,GN,GW,ML,MR,NE,SN,TD,TG
   National :AE,AL,AM,AT,AZ,BA,BB,BY,CH,CU,DK,EE,ES,FI,GB,GD,GE,GH,GM,HR,HU,
   ID,IN,IS,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MD,MG,MK,MW,MX,PT,SD,SG,SI,SL,TJ,
   TM,TR,TT,UA,UG,UZ,VN,YU,ZA,ZW

3. The applicant is reminded that he must enter the "national phase" **before the expiration of 30 months from the priority date** before each of the Offices listed above. This must be done by paying the national fee(s) and furnishing , if prescribed, a translation of the international application (Article 39(1)(a)), as well as, where applicable, by furnishing a translation of any annexes of the international preliminary examination report (Article 36(3)(b) and Rule 74.1).

   Some offices have fixed time limits expiring later than the above-mentioned time limit. For detailed information about the applicable time limits and the acts to be performed upon entry into the national phase before a particular Office, see Volume II of the PCT Applicant's Guide.

   The entry into the European regional phase is postponed **until 31 months from the priority date** for all States designated for the purposes of obtaining a European patent.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer: **Claudio Borton**
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

Form PCT/IB/332 (September 1997)

3115638

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF RECEIPT OF RECORD COPY

(PCT Rule 24.2(a))

From the INTERNATIONAL BUREAU

To:

DIRCHANSKI, Stefan, J.
Graham & James LLP
14th floor
801 S. Figueroa Street
Los Angeles, CA 90017-5554
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year) 25 May 1999 (25.05.99)	**IMPORTANT NOTIFICATION**
Applicant's or agent's file reference 36316.00005	International application No. PCT/US99/06700

The applicant is hereby notified that the International Bureau has received the record copy of the international application as detailed below.

Name(s) of the applicant(s) and State(s) for which they are applicants:

REGENTS OF THE UNIVERSITY OF CALIFORNIA (for all designated States except US)
ROBINSON, W., Edward, Jr. et al (for US)

International filing date	:	26 March 1999 (26.03.99)
Priority date(s) claimed	:	27 March 1998 (27.03.98) 17 July 1998 (17.07.98)
Date of receipt of the record copy by the International Bureau	:	04 May 1999 (04.05.99)
List of designated Offices	:	

AP :GH,GM,KE,LS,MW,SD,SZ,UG,ZW
EA :AM,AZ,BY,KG,KZ,MD,RU,TJ,TM
EP :AT,BE,CH,CY,DE,DK,ES,FI,FR,GB,GR,IE,IT,LU,MC,NL,PT,SE
OA :BF,BJ,CF,CG,CI,CM,GA,GN,GW,ML,MR,NE,SN,TD,TG
National :AE,AL,AM,AT,AU,AZ,BA,BB,BG,BR,BY,CA,CH,CN,CU,CZ,DE,DK,EE,ES,FI,GB,GD,GE,
GH,GM,HR,HU,ID,IL,IN,IS,JP,KE,KG,KP,KR,KZ,LC,LK,LR,LS,LT,LU,LV,MD,MG,MK,MN,MW,MX,
NO,NZ,PL,PT,RO,RU,SD,SE,SG,SI,SK,SL,TJ,TM,TR,TT,UA,UG,US,UZ,VN,YU,ZA,ZW

ATTENTION

The applicant should carefully check the data appearing in this Notification. In case of any discrepancy between these data and the indications in the international application, the applicant should immediately inform the International Bureau.

In addition, the applicant's attention is drawn to the information contained in the Annex, relating to:

[X] time limits for entry into the national phase

[ ] confirmation of precautionary designations

[X] requirements regarding priority documents

A copy of this Notification is being sent to the receiving Office and to the International Searching Authority.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer: G. Bähr
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

Form PCT/IB/301 (July 1998)

002635242

82351.0004 UCLA SK/SK

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

KIRCHANSKI, Stefan, J.
Hogan & Hartson LLP
Biltmore Tower, Suite 1900
500 South Grand Avenue
Los Angeles, CA 90017
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 24 July 2000 (24.07.00)	
Applicant's or agent's file reference 36316.00005	**IMPORTANT NOTIFICATION**
International application No. PCT/US99/06700	**International filing date (day/month/year)** 26 March 1999 (26.03.99)

1. The following indications appeared on record concerning:

☐ the applicant   ☐ the inventor   ☒ the agent   ☐ the common representative

Name and Address KIRCHANSKI, Stefan, J. Graham & James LLP 14th floor 801 S. Figueroa Street Los Angeles, CA 90017-5554 United States of America	State of Nationality	State of Residence
	Telephone No. 213 624 2500	
	Facsimile No. 213 623 4581	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person   ☐ the name   ☒ the address   ☐ the nationality   ☐ the residence

Name and Address KIRCHANSKI, Stefan, J. Hogan & Hartson LLP Biltmore Tower, Suite 1900 500 South Grand Avenue Los Angeles, CA 90017 United States of America	State of Nationality	State of Residence
	Telephone No. 213 337 6700	
	Facsimile No. 213 337 6701	
	Teleprinter No.	

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office
☐ the International Searching Authority
☒ the International Preliminary Examining Authority

☐ the designated Offices concerned
☒ the elected Offices concerned
☐ other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer G. Bähr Telephone No.: (41-22) 338.83.38

Form PCT/IB/306 (March 1994)

003426130

INFORMATION ON TIME LIMITS FOR ENTERING THE NATIONAL PHASE

The applicant is reminded that the "national phase" must be entered before each of the designated Offices indicated in the Notification of Receipt of Record Copy (Form PCT/IB/301) by paying national fees and furnishing translations, as prescribed by the applicable national laws.

The time limit for performing these procedural acts is **20 MONTHS** from the priority date or, for those designated States which the applicant elects in a demand for international preliminary examination or in a later election, **30 MONTHS** from the priority date, provided that the election is made before the expiration of 19 months from the priority date. Some designated (or elected) Offices have fixed time limits which expire even later than 20 or 30 months from the priority date. In other Offices an extension of time or grace period, in some cases upon payment of an additional fee, is available.

In addition to these procedural acts, the applicant may also have to comply with other special requirements applicable in certain Offices. **It is the applicant's responsibility** to ensure that the necessary steps to enter the national phase are taken in a timely fashion. Most designated Offices do not issue reminders to applicants in connection with the entry into the national phase.

For detailed information about the procedural acts to be performed to enter the national phase before each designated Office, the applicable time limits and possible extensions of time or grace periods, and any other requirements, see the relevant Chapters of Volume II of the PCT Applicant's Guide. Information about the requirements for filing a demand for international preliminary examination is set out in Chapter IX of Volume I of the PCT Applicant's Guide.

GR and ES became bound by PCT Chapter II on 7 September 1996 and 6 September 1997, respectively, and may, therefore, be elected in a demand or a later election filed on or after 7 September 1996 and 6 September 1997, respectively, regardless of the filing date of the international application. (See second paragraph above.)

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

CONFIRMATION OF PRECAUTIONARY DESIGNATIONS

This notification lists only specific designations made under Rule 4.9(a) in the request. It is important to check that these designations are correct. Errors in designations can be corrected where precautionary designations have been made under Rule 4.9(b). The applicant is hereby reminded that any precautionary designations may be confirmed according to Rule 4.9(c) before the expiration of 15 months from the priority date. If it is not confirmed, it will automatically be regarded as withdrawn by the applicant. There will be no reminder and no invitation. Confirmation of a designation consists of the filing of a notice specifying the designated State concerned (with an indication of the kind of protection or treatment desired) and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.

REQUIREMENTS REGARDING PRIORITY DOCUMENTS

For applicants who have not yet complied with the requirements regarding priority documents, the following is recalled.

Where the priority of an earlier national, regional or international application is claimed, the applicant must submit a copy of the said earlier application, certified by the authority with which it was filed ("the priority document") to the receiving Office (which will transmit it to the International Bureau) or directly to the International Bureau, before the expiration of 16 months from the priority date, provided that any such priority document may still be submitted to the International Bureau before that date of international publication of the international application, in which case that document will be considered to have been received by the International Bureau on the last day of the 16-month time limit (Rule 17.1(a)).

Where the priority document is issued by the receiving Office, the applicant may, instead of submitting the priority document, request the receiving Office to prepare and transmit the priority document to the International Bureau. Such request must be made before the expiration of the 16-month time limit and may be subjected by the receiving Office to the payment of a fee (Rule 17.1(b)).

If the priority document concerned is not submitted to the International Bureau or if the request to the receiving Office to prepare and transmit the priority document has not been made (and the corresponding fee, if any, paid) within the applicable time limit indicated under the preceding paragraphs, any designated State may disregard the priority claim, provided that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity to furnish the priority document within a time limit which is reasonable under the circumstances.

Where several priorities are claimed, the priority date to be considered for the purposes of computing the 16-month time limit is the filing date of the earliest application whose priority is claimed.